
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3EAuthor Manuscript%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Enthalpy-driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="8E59AC73925ED3A33AAC7300543B95A5.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="nihpa">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="manuscript">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6276790/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Journal of medicinal chemistry">
<meta name="citation_title" content="Enthalpy-driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis">
<meta name="citation_author" content="Mark Miller">
<meta name="citation_author_institution" content="Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.">
<meta name="citation_author_institution" content="These authors contributed equally.">
<meta name="citation_author" content="Arindom Pal">
<meta name="citation_author_institution" content="Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.">
<meta name="citation_author_institution" content="These authors contributed equally.">
<meta name="citation_author" content="Wabel Albusairi">
<meta name="citation_author_institution" content="Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.">
<meta name="citation_author_institution" content="These authors contributed equally.">
<meta name="citation_author" content="Hyun Joo">
<meta name="citation_author_institution" content="Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.">
<meta name="citation_author" content="Beverly Pappas">
<meta name="citation_author_institution" content="Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.">
<meta name="citation_author" content="Md Tariqul Haque Tuhin">
<meta name="citation_author_institution" content="Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.">
<meta name="citation_author" content="Dengpan Liang">
<meta name="citation_author_institution" content="Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.">
<meta name="citation_author" content="Raghavendra Jampla">
<meta name="citation_author_institution" content="Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.">
<meta name="citation_author" content="Fang Liu">
<meta name="citation_author_institution" content="Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.">
<meta name="citation_author" content="Jared Khan">
<meta name="citation_author_institution" content="Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.">
<meta name="citation_author" content="Marjon Faaij">
<meta name="citation_author_institution" content="Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.">
<meta name="citation_author" content="Miki Park">
<meta name="citation_author_institution" content="Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.">
<meta name="citation_author" content="William Chan">
<meta name="citation_author_institution" content="Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.">
<meta name="citation_author" content="Isabella Graef">
<meta name="citation_author_institution" content="Department of Pathology, Stanford University, Stanford, California 94305, USA">
<meta name="citation_author" content="Robert Zamboni">
<meta name="citation_author_institution" content="Eidos Therapeutics, Inc., San Francisco, California 94101, USA">
<meta name="citation_author" content="Neil Kumar">
<meta name="citation_author_institution" content="Eidos Therapeutics, Inc., San Francisco, California 94101, USA">
<meta name="citation_author" content="Jonathan Fox">
<meta name="citation_author_institution" content="Eidos Therapeutics, Inc., San Francisco, California 94101, USA">
<meta name="citation_author" content="Uma Sinha">
<meta name="citation_author_institution" content="Eidos Therapeutics, Inc., San Francisco, California 94101, USA">
<meta name="citation_author" content="Mamoun Alhamadsheh">
<meta name="citation_author_institution" content="Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.">
<meta name="citation_publication_date" content="2018 Aug 22">
<meta name="citation_volume" content="61">
<meta name="citation_issue" content="17">
<meta name="citation_firstpage" content="7862">
<meta name="citation_doi" content="10.1021/acs.jmedchem.8b00817">
<meta name="citation_pmid" content="30133284">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC6276790/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC6276790/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC6276790/pdf/nihms-996579.pdf">
<meta name="description" content="Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a fatal disease with no available disease-modifying therapies. While pathogenic TTR mutations (TTRm) destabilize TTR tetramers, the T119M variant stabilizes TTRm and prevents disease. A ...">
<meta name="og:title" content="Enthalpy-driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a fatal disease with no available disease-modifying therapies. While pathogenic TTR mutations (TTRm) destabilize TTR tetramers, the T119M variant stabilizes TTRm and prevents disease. A ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC6276790/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="6276790">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1021/acs.jmedchem.8b00817"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/nihms-996579.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC6276790%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/6276790/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/6276790/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC6276790/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-nihpa.png" alt="NIHPA Author Manuscripts logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to NIHPA Author Manuscripts" title="Link to NIHPA Author Manuscripts" shape="default" href="https://www.hhs.gov/open/public-access-guiding-principles/index.html" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">J Med Chem</button></div>. Author manuscript; available in PMC: 2019 Sep 13.</div>
<div>
<em>Published in final edited form as: </em>J Med Chem. 2018 Aug 22;61(17):7862–7876. doi: <a href="https://doi.org/10.1021/acs.jmedchem.8b00817" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1021/acs.jmedchem.8b00817</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22J%20Med%20Chem%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22J%20Med%20Chem%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J%20Med%20Chem%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22J%20Med%20Chem%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Enthalpy-driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Miller%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Mark Miller</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Mark Miller</span></h3>
<div class="p">
<sup>†</sup>Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.</div>
<div class="p">
<sup>┴</sup>These authors contributed equally.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Miller%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mark Miller</span></a>
</div>
</div>
<sup>†,</sup><sup>┴</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pal%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Arindom Pal</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Arindom Pal</span></h3>
<div class="p">
<sup>†</sup>Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.</div>
<div class="p">
<sup>┴</sup>These authors contributed equally.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pal%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Arindom Pal</span></a>
</div>
</div>
<sup>†,</sup><sup>┴</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Albusairi%20W%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Wabel Albusairi</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Wabel Albusairi</span></h3>
<div class="p">
<sup>†</sup>Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.</div>
<div class="p">
<sup>┴</sup>These authors contributed equally.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Albusairi%20W%22%5BAuthor%5D" class="usa-link"><span class="name western">Wabel Albusairi</span></a>
</div>
</div>
<sup>†,</sup><sup>┴</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Joo%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Hyun Joo</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Hyun Joo</span></h3>
<div class="p">
<sup>†</sup>Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Joo%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hyun Joo</span></a>
</div>
</div>
<sup>†</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pappas%20B%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Beverly Pappas</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Beverly Pappas</span></h3>
<div class="p">
<sup>†</sup>Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pappas%20B%22%5BAuthor%5D" class="usa-link"><span class="name western">Beverly Pappas</span></a>
</div>
</div>
<sup>†</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tuhin%20MTH%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Md Tariqul Haque Tuhin</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Md Tariqul Haque Tuhin</span></h3>
<div class="p">
<sup>†</sup>Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tuhin%20MTH%22%5BAuthor%5D" class="usa-link"><span class="name western">Md Tariqul Haque Tuhin</span></a>
</div>
</div>
<sup>†</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liang%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Dengpan Liang</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Dengpan Liang</span></h3>
<div class="p">
<sup>†</sup>Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liang%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Dengpan Liang</span></a>
</div>
</div>
<sup>†</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jampla%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Raghavendra Jampla</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Raghavendra Jampla</span></h3>
<div class="p">
<sup>†</sup>Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jampla%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Raghavendra Jampla</span></a>
</div>
</div>
<sup>†</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Fang Liu</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Fang Liu</span></h3>
<div class="p">
<sup>†</sup>Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Fang Liu</span></a>
</div>
</div>
<sup>†</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Khan%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Jared Khan</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Jared Khan</span></h3>
<div class="p">
<sup>†</sup>Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Khan%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jared Khan</span></a>
</div>
</div>
<sup>†</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Faaij%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Marjon Faaij</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Marjon Faaij</span></h3>
<div class="p">
<sup>†</sup>Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Faaij%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Marjon Faaij</span></a>
</div>
</div>
<sup>†</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Park%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Miki Park</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Miki Park</span></h3>
<div class="p">
<sup>†</sup>Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Park%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Miki Park</span></a>
</div>
</div>
<sup>†</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chan%20W%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">William Chan</span></a><div hidden="hidden" id="id13">
<h3><span class="name western">William Chan</span></h3>
<div class="p">
<sup>†</sup>Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chan%20W%22%5BAuthor%5D" class="usa-link"><span class="name western">William Chan</span></a>
</div>
</div>
<sup>†</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Graef%20I%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Isabella Graef</span></a><div hidden="hidden" id="id14">
<h3><span class="name western">Isabella Graef</span></h3>
<div class="p">
<sup>‡</sup>Department of Pathology, Stanford University, Stanford, California 94305, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Graef%20I%22%5BAuthor%5D" class="usa-link"><span class="name western">Isabella Graef</span></a>
</div>
</div>
<sup>‡</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zamboni%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Robert Zamboni</span></a><div hidden="hidden" id="id15">
<h3><span class="name western">Robert Zamboni</span></h3>
<div class="p">
<sup>§</sup>Eidos Therapeutics, Inc., San Francisco, California 94101, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zamboni%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Robert Zamboni</span></a>
</div>
</div>
<sup>§</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kumar%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">Neil Kumar</span></a><div hidden="hidden" id="id16">
<h3><span class="name western">Neil Kumar</span></h3>
<div class="p">
<sup>§</sup>Eidos Therapeutics, Inc., San Francisco, California 94101, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kumar%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Neil Kumar</span></a>
</div>
</div>
<sup>§</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fox%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id17"><span class="name western">Jonathan Fox</span></a><div hidden="hidden" id="id17">
<h3><span class="name western">Jonathan Fox</span></h3>
<div class="p">
<sup>§</sup>Eidos Therapeutics, Inc., San Francisco, California 94101, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fox%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jonathan Fox</span></a>
</div>
</div>
<sup>§</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sinha%20U%22%5BAuthor%5D" class="usa-link" aria-describedby="id18"><span class="name western">Uma Sinha</span></a><div hidden="hidden" id="id18">
<h3><span class="name western">Uma Sinha</span></h3>
<div class="p">
<sup>§</sup>Eidos Therapeutics, Inc., San Francisco, California 94101, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sinha%20U%22%5BAuthor%5D" class="usa-link"><span class="name western">Uma Sinha</span></a>
</div>
</div>
<sup>§,</sup><sup>*</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alhamadsheh%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id19"><span class="name western">Mamoun Alhamadsheh</span></a><div hidden="hidden" id="id19">
<h3><span class="name western">Mamoun Alhamadsheh</span></h3>
<div class="p">
<sup>†</sup>Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alhamadsheh%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mamoun Alhamadsheh</span></a>
</div>
</div>
<sup>†,</sup><sup>*</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="A1">
<sup>†</sup>Department of Pharmaceutics &amp; Medicinal Chemistry, University of the Pacific, Stockton, California 95211, USA.</div>
<div id="A2">
<sup>‡</sup>Department of Pathology, Stanford University, Stanford, California 94305, USA</div>
<div id="A3">
<sup>§</sup>Eidos Therapeutics, Inc., San Francisco, California 94101, USA</div>
<div id="A4">
<sup>┴</sup>These authors contributed equally.</div>
<div class="author-notes p">
<div class="fn" id="FN1">
<sup>#</sup><p class="display-inline" id="P1">Author Contributions</p>
<p id="P2">M.M., A.P., and W.B. contributed equally, and U.S. and M.A. are considered senior authors.</p>
</div>
<div class="fn" id="CR1">
<sup>*</sup><p class="display-inline"><strong>Corresponding Authors:</strong><span>malhamadsheh@pacific.edu</span> (M.A.), <span>usinha@eidostx.com</span> (U.S.).</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Issue date 2018 Sep 13.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none"><div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div></div>
</div>
<div>PMCID: PMC6276790  NIHMSID: NIHMS996579  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/30133284/" class="usa-link">30133284</a>
</div>
<div class="ra xbox p" role="complementary" aria-label="Related or updated information about this article"><div>The publisher's version of this article is available at <a href="https://doi.org/10.1021/acs.jmedchem.8b00817" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">J Med Chem</a>
</div></div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="ABS1"><h2>Abstract</h2>
<p id="P3">Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a fatal disease with no available disease-modifying therapies. While pathogenic TTR mutations (TTRm) destabilize TTR tetramers, the T119M variant stabilizes TTRm and prevents disease. A comparison of potency for leading TTR stabilizers in clinic and structural features important for effective TTR stabilization is lacking. Here, we found that molecular interactions reflected in better binding enthalpy may be critical for development of TTR stabilizers with improved potency and selectivity. Our studies provide mechanistic insights into the unique binding mode of the TTR stabilizer, AG10, which could be attributed to mimicking the stabilizing T119M variant. Due to the lack of animal models for ATTR-CM, we developed an <em>in vivo</em> system in dogs which proved appropriate for assessing the Pharmacokinetics/pharmacodynamics profile of TTR stabilizers. In addition to stabilizing TTR, we hypothesize that optimizing the binding enthalpy could have implications for designing therapeutic agents for other amyloid diseases.</p></section><section class="abstract" id="ABS2"><h2>Graphical Abstract</h2>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595e/6276790/f4aba4401d99/nihms-996579-f0001.jpg" loading="lazy" height="259" width="450" alt="graphic file with name nihms-996579-f0001.jpg"></p></section><section id="S1"><h2 class="pmc_sec_title">INTRODUCTION</h2>
<p id="P5">Transthyretin (TTR) amyloidosis (ATTR) is a progressive, fatal disease in which deposition of amyloid derived from either mutant (TTRm) or wild-type (TTRwt) TTR causes severe organ damage and dysfunction.<sup><a href="#R1" class="usa-link" aria-describedby="R1">1</a>, <a href="#R2" class="usa-link" aria-describedby="R2">2</a></sup> Clinically, ATTR presents as cardiomyopathy (ATTR-CM) or peripheral polyneuropathy (ATTR-PN). ATTR-CM is an infiltrative, restrictive cardiomyopathy characterized by progressive left and right heart failure. Familial ATTR-CM (ATTRm-CM) is driven by pathogenic, autosomal dominant, point mutations resulting in amino acid substitutions that destabilize the native TTR tetramer, prompting its dissociation.<sup><a href="#R3" class="usa-link" aria-describedby="R3">3</a>, <a href="#R4" class="usa-link" aria-describedby="R4">4</a></sup> The most prevalent mutation that causes ATTRm-CM is the V122I variant, carried by 3.4% of African Americans, which increases the risk of ATTR-CM several-fold in this population.<sup><a href="#R5" class="usa-link" aria-describedby="R5">5</a>, <a href="#R6" class="usa-link" aria-describedby="R6">6</a></sup> In addition, older individuals may develop ATTR derived from wild-type TTR (ATTRwt-CM). The average life expectancy for people with ATTR-CM is 3 to 5 years from diagnosis.<sup><a href="#R7" class="usa-link" aria-describedby="R7">7</a></sup> Unfortunately, ATTR-CM represents one of the largest genetically-defined diseases with no approved disease-modifying therapies.</p>
<p id="P6">The TTR tetramer features two largely unoccupied thyroxine (T4)-binding sites that are formed between adjacent monomers at the weaker dimer–dimer interface of TTR. Tetramer dissociation into dimers, and then monomers, is the initial and rate-limiting step in TTR amyloidogenesis.<sup><a href="#R2" class="usa-link" aria-describedby="R2">2</a></sup> The majority of TTR mutations increase the amyloidogenic potential of TTR by lowering its thermodynamic stability and/or decreasing the kinetic barrier for tetramer dissociation.<sup><a href="#R8" class="usa-link" aria-describedby="R8">8</a></sup> While the V122I variant associated with ATTRm-CM is kinetically destabilized, ATTR-PN is predominantly associated with the thermodynamically destabilized V30M-TTR variant.<sup><a href="#R9" class="usa-link" aria-describedby="R9">9</a>, <a href="#R10" class="usa-link" aria-describedby="R10">10</a></sup></p>
<p id="P7">Two TTR variants, T119M and R104H, have been shown to hyper-stabilize hetero-tetramers composed of these variants and either TTRwt or TTRm, preventing amyloidogenesis <em>in vitro</em>.<sup><a href="#R9" class="usa-link" aria-describedby="R9">9</a>, <a href="#R11" class="usa-link" aria-describedby="R11">11</a></sup> Individuals who are compound heterozygous for both the T119M variant and the polyneuropathy associated V30M-TTR mutation present a more benign evolution of ATTR-PN or no disease compared to kindred carrying the V30M-TTR mutation alone.<sup><a href="#R12" class="usa-link" aria-describedby="R12">12</a></sup> In addition, carriage of the T119M rescue mutation in the absence of other destabilizing TTR mutations has been correlated with a decreased risk of vascular disease and increased life expectancy, as compared to the general (non-carrier) population, by 5–10 years.<sup><a href="#R13" class="usa-link" aria-describedby="R13">13</a></sup> Similar effects have been described for the R104H-TTR variant in Japanese individuals expressing both R104H and V30M-TTR.<sup><a href="#R14" class="usa-link" aria-describedby="R14">14</a></sup> The trans-suppressor effects of T119M and R104H are based on different mechanisms.<sup><a href="#R11" class="usa-link" aria-describedby="R11">11</a></sup> While the T119M kinetically stabilizes the quaternary structure of TTR, the R104H variant is thermodynamically stabilized. Therefore, the stabilizing effect of the T119M mutation is much greater than that of R104H, which only modestly protects against TTR dissociation and aggregation <em>in vitro</em>.</p>
<p id="P8">Emerging therapies for ATTR-CM include RNA silencing therapies and TTR stabilizers which are small molecules that bind to the TTR T4 binding sites, thereby stabilizing TTR by increasing the energy barrier of tetramer dissociation.<sup><a href="#R3" class="usa-link" aria-describedby="R3">3</a></sup> Tafamidis and AG10 are two orally available TTR stabilizers currently in clinical development for ATTR-CM (Phase 3 and Phase 2, respectively). In addition, diflunisal and tolcapone are two repurposed drugs that have been investigated in ATTR-PN. We have shown earlier that the despite the similar binding affinities (<em>K</em><sub>d</sub>) of AG10 and tafamidis to TTR (<em>K</em><sub>d</sub> = 4.8 ± 1.9 and 4.4 ± 1.3 nM, respectively), AG10 was more potent (in stabilizing TTR in buffer) and more selective for binding and stabilizing TTR in human serum.<sup><a href="#R15" class="usa-link" aria-describedby="R15">15</a></sup> In order to account for structural features important for effective TTR stabilization, we performed a side-by-side comparison of the structural, thermodynamic properties, and potency for all ATTR clinical candidates against the crystal structures of stabilizing TTR variants (T119M and R104H). We found that the <em>K</em><sub>d</sub> between a stabilizer and TTR does not correlate well with either potency or selectivity (<a href="#T1" class="usa-link">Table 1</a>). The mechanistic insights gained from our studies suggest that optimizing the enthalpic component of binding plays a crucial if not predominant role in stabilizing TTR. This conclusion was also supported by the synthesis and evaluation of the activity of four new AG10 analogues (compounds <strong>1</strong>, <strong>2</strong>, <strong>3</strong>, and <strong>4</strong>). Several previous studies have shown that enthalpic forces correlated with selectivity of ligands to target proteins including TTR.<sup><a href="#R16" class="usa-link" aria-describedby="R16">16</a>, <a href="#R17" class="usa-link" aria-describedby="R17">17</a></sup> However, there are no reports describing the role of enthalpy in enhancing the potency of ligands in stabilizing multi-subunit protein complexes. Our data show that the high potency of AG10 could be attributed to its enthalpically-driven binding, mimicking the disease-suppressing properties of the T119M-TTR variant in stabilizing TTR. The potency and selectivity of AG10 for TTR was maintained when AG10 was evaluated in beagle dogs <em>in vivo</em>. To the best of our knowledge, this is the first report describing a correlation between enthalpic binding of a ligand and enhanced potency in stabilizing multi-protein complexes.</p>
<section class="tw xbox font-sm" id="T1"><h3 class="obj_head">Table 1.</h3>
<div class="caption p"><p id="P73">Comparison of the binding affinity, thermodynamics, and potency of stabilizers to TTR in buffer and human serum.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="box" rules="all">
<colgroup span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
</colgroup>
<thead>
<tr>
<th rowspan="2" align="center" valign="middle" colspan="1">Stabilizer</th>
<th rowspan="2" align="center" valign="middle" colspan="1">
<em>K</em><sub>d</sub><br>(nM)</th>
<th colspan="3" align="center" valign="middle" style="border-bottom-style: hidden" rowspan="1">ITC Parameters (kcal/mol)</th>
<th rowspan="2" align="center" valign="middle" colspan="1">%TTR Occupancy in Buffer (1:1 ratio)<sup><a href="#TFN1" class="usa-link">a</a></sup>
</th>
<th rowspan="2" align="center" valign="middle" colspan="1">%TTR Occupancy in Serum (2:1 ratio)<sup><a href="#TFN1" class="usa-link">a</a></sup>
</th>
<th rowspan="2" align="center" valign="middle" colspan="1">%TTR Stabilization in Serum (2:1 ratio)<sup><a href="#TFN1" class="usa-link">a</a></sup>
</th>
</tr>
<tr>
<th align="center" valign="middle" style="border-right-style: hidden" rowspan="1" colspan="1">Δ<em>G</em>
</th>
<th align="center" valign="middle" style="border-right-style: hidden" rowspan="1" colspan="1">Δ<em>H</em>
</th>
<th align="center" valign="middle" rowspan="1" colspan="1">
<em>T</em>Δ<em>S</em>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1"><strong>AG10</strong></td>
<td align="center" valign="middle" rowspan="1" colspan="1">4.8 ± 1.9</td>
<td align="center" valign="middle" rowspan="1" colspan="1">−11.34</td>
<td align="center" valign="middle" rowspan="1" colspan="1">−13.6</td>
<td align="center" valign="middle" rowspan="1" colspan="1">−2.26</td>
<td align="center" valign="middle" rowspan="1" colspan="1">79.1 ± 1.2</td>
<td align="center" valign="middle" rowspan="1" colspan="1">98.8 ± 2.9</td>
<td align="center" valign="middle" rowspan="1" colspan="1">95.4 ± 2.9</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1"><strong>Tafamidis</strong></td>
<td align="center" valign="middle" rowspan="1" colspan="1">4.4 ± 1.3</td>
<td align="center" valign="middle" rowspan="1" colspan="1">−11.39</td>
<td align="center" valign="middle" rowspan="1" colspan="1">−5.0</td>
<td align="center" valign="middle" rowspan="1" colspan="1">6.39</td>
<td align="center" valign="middle" rowspan="1" colspan="1">49.9 ± 3.3</td>
<td align="center" valign="middle" rowspan="1" colspan="1">49 ± 3.3</td>
<td align="center" valign="middle" rowspan="1" colspan="1">41.5 ± 4.6</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1"><strong>Diflunisal</strong></td>
<td align="center" valign="middle" rowspan="1" colspan="1">407 ± 35</td>
<td align="center" valign="middle" rowspan="1" colspan="1">−8.72</td>
<td align="center" valign="middle" rowspan="1" colspan="1">−8.38</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.34</td>
<td align="center" valign="middle" rowspan="1" colspan="1">28.7 ± 0.6</td>
<td align="center" valign="middle" rowspan="1" colspan="1">16.2 ± 3.2</td>
<td align="center" valign="middle" rowspan="1" colspan="1">24.2 ± 2.3</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1"><strong>Tolcapone</strong></td>
<td align="center" valign="middle" rowspan="1" colspan="1">20.6 ± 3.7</td>
<td align="center" valign="middle" rowspan="1" colspan="1">−10.5</td>
<td align="center" valign="middle" rowspan="1" colspan="1">−10.1</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.4</td>
<td align="center" valign="middle" rowspan="1" colspan="1">71.7 ± 2.5</td>
<td align="center" valign="middle" rowspan="1" colspan="1">71.1 ± 2.9</td>
<td align="center" valign="middle" rowspan="1" colspan="1">68.4 ± 5.1</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1"><strong>1</strong></td>
<td align="center" valign="middle" rowspan="1" colspan="1">90 ± 14</td>
<td align="center" valign="middle" rowspan="1" colspan="1">−9.61</td>
<td align="center" valign="middle" rowspan="1" colspan="1">−9.82</td>
<td align="center" valign="middle" rowspan="1" colspan="1">−0.21</td>
<td align="center" valign="middle" rowspan="1" colspan="1">58.3 ± 0.9</td>
<td align="center" valign="middle" rowspan="1" colspan="1">75.9 ± 3.1</td>
<td align="center" valign="middle" rowspan="1" colspan="1">86.7 ± 2.3</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1"><strong>2</strong></td>
<td align="center" valign="middle" rowspan="1" colspan="1">258 ± 17</td>
<td align="center" valign="middle" rowspan="1" colspan="1">−8.99</td>
<td align="center" valign="middle" rowspan="1" colspan="1">−6.49</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2.5</td>
<td align="center" valign="middle" rowspan="1" colspan="1">38.5 ± 0.8</td>
<td align="center" valign="middle" rowspan="1" colspan="1">63.2 ± 2.5</td>
<td align="center" valign="middle" rowspan="1" colspan="1">70.4 ± 2.2</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1"><strong>3</strong></td>
<td align="center" valign="middle" rowspan="1" colspan="1">251 ± 12</td>
<td align="center" valign="middle" rowspan="1" colspan="1">−9.0</td>
<td align="center" valign="middle" rowspan="1" colspan="1">−4.73</td>
<td align="center" valign="middle" rowspan="1" colspan="1">4.27</td>
<td align="center" valign="middle" rowspan="1" colspan="1">29.7 ± 0.7</td>
<td align="center" valign="middle" rowspan="1" colspan="1">43 ± 0.6</td>
<td align="center" valign="middle" rowspan="1" colspan="1">32.1 ± 4.9</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1"><strong>4</strong></td>
<td align="center" valign="middle" rowspan="1" colspan="1">1253 ± 79</td>
<td align="center" valign="middle" rowspan="1" colspan="1">−8.1</td>
<td align="center" valign="middle" rowspan="1" colspan="1">−2.1</td>
<td align="center" valign="middle" rowspan="1" colspan="1">6.0</td>
<td align="center" valign="middle" rowspan="1" colspan="1">17.2 ± 0.9</td>
<td align="center" valign="middle" rowspan="1" colspan="1">20.8 ± 3.3</td>
<td align="center" valign="middle" rowspan="1" colspan="1">23.2 ± 1.1</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/T1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="TFN1">
<sup>a</sup><p class="display-inline" id="P74">Stabilizers to TTR ratio. %TTR occupancy in buffer and human serum was determined by FPE assay. %TTR stabilization in human serum was determined by Western blot.</p>
</div></div></section></section><section id="S2"><h2 class="pmc_sec_title">RESULTS</h2>
<section id="S3"><h3 class="pmc_sec_title">Determination of Binding Affinities and Thermodynamics of Interactions Between Stabilizers and TTR.</h3>
<p id="P9">We used isothermal titration calorimetry (ITC) to determine the binding affinities (<em>K</em><sub>d</sub>) and the mechanisms underlying molecular interactions of all TTR stabilizers in clinical development (i.e. AG10, tafamidis, diflunisal and tolcapone) and AG10 analogues <strong>1</strong>, <strong>2</strong>, <strong>3</strong>, and <strong>4</strong>. Most of the reported TTR ligands bind to the two identical T4 binding sites of TTR with strong negative cooperativity and therefore the binding of the first ligand will dominate the total binding energy as well as the stabilizing effect. While some differences in cooperativity can be observed in the ITC thermograms, these differences will have minor influences on the binding energy as well as the stabilizing effect. Therefore, the <em>K</em><sub>d</sub> values reported in <a href="#T1" class="usa-link">Table 1</a> were based on data fitted to independent single-site binding model.<sup><a href="#R16" class="usa-link" aria-describedby="R16">16</a></sup> The binding affinities of AG10 and tafamidis to TTR in buffer (<em>K</em><sub>d</sub> = 4.8 ± 1.9 and 4.4 ± 1.3 nM, respectively) were 4-fold higher than tolcapone (<em>K</em><sub>d</sub> = 20.6 ± 3.7 nM) and ~100-fold higher than diflunisal (<em>K</em><sub>d</sub> = 407 ± 35 nM). The <em>K</em><sub>d</sub> values for compounds <strong>1</strong>-<strong>4</strong> ranged from 90 to 1250 nM, and the results are summarized in <a href="#T1" class="usa-link">Table 1</a>. The <em>K</em><sub>d</sub> for binding of a stabilizer to TTR is represented by the change in Gibbs free energy of binding (Δ<em>G</em>), where Δ<em>G =</em> Δ<em>H – T</em>Δ<em>S</em>. By analyzing the thermodynamic signature of each molecule, we can assess the relative contributions of enthalpic (Δ<em>H</em>; representing the formation or breaking of chemical bonds) and entropic forces (Δ<em>S</em>; associated with the amount of disorder in a system and frequently dominated and favored by release of bound water molecule due to hydrophobic interactions). Despite the similar binding affinities of AG10 and tafamidis to TTR in buffer (i.e., similar Δ<em>G</em> values), their binding energetics to TTR are notably different. Whereas the binding of AG10 (Δ<em>H</em> = −13.60 kcal/mol and <em>T</em>Δ<em>S</em> = −2.26 kcal/mol) is enthalpically driven, tafamidis binding is approximately 50% entropic and 50% enthalpic (Δ<em>H</em> = −5.00 kcal/mol and <em>T</em>Δ<em>S</em> = 6.39 kcal/mol) (<a href="#F1" class="usa-link">Figure 1a</a> and <a href="#T1" class="usa-link">Table 1</a>). The binding of tolcapone (Δ<em>H</em> = −10.1 kcal/mol and <em>T</em>Δ<em>S</em> = 0.4 kcal/mol) and diflunisal (Δ<em>H</em> = −8.38 kcal/mol and <em>T</em>Δ<em>S</em> = 0.34 kcal/mol) is entropically favorable but mainly driven by enthalpic interactions. The unfavorable entropic binding energy of AG10 for TTR (<em>T</em>Δ<em>S</em> = −2.26 kcal/mol) could be due to its higher polarity and/or conformational flexibility compared to other TTR stabilizers. The themodynamics for the binding interactions between compounds <strong>1</strong>-<strong>4</strong> and TTR is discussed below.</p>
<figure class="fig xbox font-sm" id="F1"><h4 class="obj_head">Figure 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6276790_nihms-996579-f0002.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595e/6276790/b0dcb0a99541/nihms-996579-f0002.jpg" loading="lazy" height="749" width="800" alt="Figure 1."></a></p>
<div class="p text-right font-secondary"><a href="figure/F1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p id="P65">Binding Affinities and Potency of Stabilizers for TTR in Buffer. (a) Interaction of TTR with stabilizers assessed by ITC. Thermodynamic data (summarized in <a href="#T1" class="usa-link">Table 1</a>); ΔG are blue bars, ΔH are green bars, and -TΔS are red bars. (b) Fluorescence change caused by modification of TTR in buffer (2.5 μM) by FPE probe monitored in the presence of probe alone (Control DMSO) or TTR stabilizers (2.5 μM; 1:1 Stabilizers to TTR ratio). (c) Bar graph representation of percent occupancy of TTR in buffer by stabilizers in the presence of FPE probe measured after 3 hr of incubation relative to probe alone. Error bars indicate SD (n = 3). The significance of the differences were measured by one-way ANOVA followed by Tukey’s multiple comparison test (*p ≤ 0.05; ***p ≤ 0.001).</p></figcaption></figure></section><section id="S4"><h3 class="pmc_sec_title">Enthalpic Force Predicts Potency of TTR Stabilizers in Buffer and Efficacy in Human Serum.</h3>
<p id="P10">A recent study with diflunisal and other nonsteroidal anti-inflammatory drugs (NSAIDs) found that ligands with favorable (i.e. larger negative) Δ<em>H</em> had a proportionally higher TTR selectivity compared to ligands with a lower influence of Δ<em>H</em>.<sup><a href="#R16" class="usa-link" aria-describedby="R16">16</a></sup> While this study described the correlation between enthalpic forces and selectivity of TTR stabilizers, no correlation between binding enthalpy of ligands and potency for stabilizing TTR or, to our knowledge, any other multimeric proteins has been reported yet. To evaluate the potency of stabilizers in occupying and stabilizing TTR in buffer we used the fluorescence probe exclusion (FPE) assay.<sup><a href="#R18" class="usa-link" aria-describedby="R18">18</a></sup> The FPE assay uses a fluorogenic probe (FPE probe, <a href="#SD1" class="usa-link">Supplementary Figure 1</a>) that is not fluorescent by itself, however upon binding to the T4 binding site of TTR it covalently modifies lysine 15 (K15), creating a fluorescent conjugate. Ligands that bind to the T4 site of TTR will decrease FPE probe binding as observed by lower fluorescence. A linear correlation has been reported between the extent of fluorescence in the FPE assay and stabilization of TTR.<sup><a href="#R18" class="usa-link" aria-describedby="R18">18</a></sup> Therefore, we first used the FPE assay to measure the potency of stabilizers for binding and stabilizing TTR in buffer (tested at 1:1 ratio of stabilizer to TTR tetramer; <a href="#F1" class="usa-link">Figure 1b,c</a> and <a href="#T1" class="usa-link">Table 1</a>). The order of potency of the stabilizers for TTR in buffer was AG10 &gt; tolcapone &gt; tafamidis &gt; diflunisal.</p>
<p id="P11">We then employed the FPE and Western blot assays to evaluate the efficacy (representing both potency and selectivity) of stabilizers (10 μM) in occupying and stabilizing TTR in human serum (TTR concentration 5 μM) (<a href="#T1" class="usa-link">Table 1</a>). The Western blot assay measures the amount of intact TTR tetramer after 72 h of acid treatment in the presence and absence of stabilizers. The order of efficacy of the stabilizers in human serum was similar to what we observed for the potency with TTR in buffer (AG10 &gt; tolcapone &gt; tafamidis &gt; diflunisal; <a href="#T1" class="usa-link">Table 1</a>). The potency and efficacy of diflunisal was the lowest which is predicted based on its significantly lower binding affinity to TTR (<em>K</em><sub>d</sub> = 407 ± 35 nM) compared to all other stabilizers (20 to 80-fold lower affinity than other stabilizers). Surprisingly, there was no correlation between the <em>K</em><sub>d</sub> values of the three other stabilizers and their potency and efficacy in occupying and stabilizing TTR in both buffer and human serum. For example, the potency and efficacy of tolcapone was higher than that of tafamidis despite the fact that the binding affinity of tolcapone to TTR (<em>K</em><sub>d</sub> = 20.6 ± 3.7 nM) is slightly lower than the binding affinity of tafamidis to TTR (<em>K</em><sub>d</sub> = 4.4 ± 1.3 nM). Interestingly, both potency and efficacy of these stabilizers for TTR in buffer and serum correlated very well (<em>R</em><sup><em>2</em></sup> = 0.98) with their binding enthalpy (Δ<em>H</em> = −13.6, −10.1, and −5.0 kcal/mol; for AG10, tolcapone and tafamidis, respectively). This data indicate that the enthalpically-driven binding of AG10 and tolcapone to TTR (discussed in details below) is the primary driver of their efficient stabilization of TTR compared to other stabilizers.</p>
<p id="P12">We then used the Western blot assay to compare the efficacy of AG10 (10 μM) to other stabilizers at their reported mean maximum plasma concentrations in human (C<sub>max</sub> of 20 μM for 80 mg tafamidis qd; 200 μM for diflunisal 250 mg bid; and 20 μM for tolcapone 100 mg dose tid). AG10 at 10 μM completely stabilized TTR in human serum (%TTR stabilization: 95.4 ± 4.8%); the other compounds stabilized ~50–75% of tetrameric TTR at their reported clinical C<sub>max</sub> (<a href="#F2" class="usa-link">Figure 2a,b</a>). The pKa values for AG10 (pKa = 4.13; <a href="#SD1" class="usa-link">Supplementary Figure 2</a>) and tafamidis (pKa = 3.73) are higher than that for diflunisal (pKa = 2.94). Therefore, the percentage ionization of the carboxylic acid groups of stabilizers might vary at pH 4. This could affect the strength of the electrostatic interaction between the carboxylic acid groups and the ɛ-amino groups of lysine 15 (K15) and K15′ at the top of the T4 binding sites which could affect the potency of the stabilizer. To address this concern, we performed the Western blot assay using Urea buffer (pH 7.4).<sup><a href="#R19" class="usa-link" aria-describedby="R19">19</a></sup> The TTR stabilization data of in Urea buffer (<a href="#SD1" class="usa-link">Supplementary Figure 3</a>) is similar to the data obtained from Western blot in acidic pH and from the FPE assay at physiological pH. Consistent with the Western blot TTR stabilization assay data, T4 binding site occupancy by 10 μM AG10 in the FPE assay was essentially complete (%TTR occupancy 96.6 ± 2.1%) and higher than all stabilizers at their reported clinical C<sub>max</sub>. The target occupancy for tolcapone at 20 μM (%TTR occupancy 86 ± 3.2%) was higher than those of tafamidis and diflunisal (%TTR occupancy ~65% at 20 μM and 200 μM, respectively) (<a href="#F2" class="usa-link">Figure 2c,d</a>).</p>
<figure class="fig xbox font-sm" id="F2"><h4 class="obj_head">Figure 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6276790_nihms-996579-f0003.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595e/6276790/77649a6fc2a8/nihms-996579-f0003.jpg" loading="lazy" height="623" width="900" alt="Figure 2."></a></p>
<div class="p text-right font-secondary"><a href="figure/F2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p id="P66">Efficacy of stabilizers in occupying and stabilizing TTR in human serum. (a) Representative western blot image for the stabilization of TTR in human serum subjected to acid-mediated (pH 4.0) denaturation in the presence of AG10 (10 μM) and other stabilizers tested at their estimated mean clinical C<sub>max</sub> at steady state when administered at the doses indicated: diflunisal (250 mg bid, 200 μM); tafamidis (80 mg qd), 20 μM; tolcapone (100 mg tid), 20 μM. (b) Bar graph representation of stabilization data obtained from Western blot experiments. Error bars indicate SD (n = 3). (c) Fluorescence change caused by modification of TTR in human serum by FPE probe monitored in the presence of probe alone (Control DMSO), AG10 (10 μM), or TTR stabilizers (at their estimated mean clinical steady state C<sub>max</sub>). (d) Bar graph representation of percent occupancy of TTR in human serum by stabilizers in the presence of FPE probe measured after 3 hr of incubation relative to probe alone. Error bars indicate SD (n = 4). The significance of the differences were measured by one-way ANOVA followed by Tukey’s multiple comparison test (n.s., not significant; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001)</p></figcaption></figure></section><section id="S5"><h3 class="pmc_sec_title">Binding Interactions Between AG10 and S117/S117’ of TTR Mimic Molecular Interactions within the Disease-Protective T119M Mutation.</h3>
<p id="P13">We investigated the correlation between binding enthalpy and TTR stabilization by comparing reported co-crystal structures of stabilizers with TTR against the crystal structures of stabilizing TTR variants (T119M and R104H). We hypothesized that this could allow us to identify functional groups of amino acids within the T4 binding sites of TTR which are important for binding and stabilization of TTR. The carboxylic acid moieties of AG10, tafamidis, diflunisal, and the hydroxyl group on tolcapone all participate in electrostatic interactions with the ɛ-amino groups of lysine 15 (K15) and K15′ at the top of the T4 binding sites.<sup><a href="#R15" class="usa-link" aria-describedby="R15">15</a>, <a href="#R20" class="usa-link" aria-describedby="R20">20</a>, <a href="#R21" class="usa-link" aria-describedby="R21">21</a></sup> The enthalpically driven binding of AG10 and tolcapone to TTR is driven by additional hydrogen bonds that both molecules form within the T4 binding site. The carbonyl group of tolcapone forms one hydrogen bond with hydroxyl side chain of T119 of TTRwt (distance ~2.6 Å; ideal distance for a hydrogen bond is &lt;3 Å). The longer distance between the carbonyl group of tolcapone and hydroxyl side chain of T119’ on the adjacent monomer (distance ~7.6 Å) preclude the formation of a second hydrogen bond.<sup><a href="#R20" class="usa-link" aria-describedby="R20">20</a></sup> Interestingly, this interaction is weaker between tolcapone and V122I-TTR (distance between the carbonyl group of tolcapone and hydroxyl side chains of T119 and T119’ of V122I-TTR are ~5.5 Å and ~9.6 Å, respectively), which could explain the lower binding affinity (<em>K</em><sub>d</sub> = 56 nM) and potency of tolcapone toward V122I-TTR compared to TTRwt.<sup><a href="#R20" class="usa-link" aria-describedby="R20">20</a></sup> In the case of tafamidis, there is no hydrogen bonding at the base of the T4 pocket; instead, the chlorine atoms of the 3,5-dichloro ring are also placed into halogen binding pocket (HBP) 3 and 3′, where they interact with TTR through predominantly hydrophobic interactions. In addition to electrostatic interactions between the carboxylic acid moiety of AG10 and K15/K15’, AG10 also forms two hydrogen bonds with the hydroxyl side chain serine 117 (S117) and S117′ (distance ~2.8 Å) of adjacent monomers in the low dielectric macromolecular interior of the T4 binding site (<a href="#F3" class="usa-link">Figure 3a</a>). These additional hydrogen bonds are likely to be responsible for the driving force for the dominant enthalpic binding of AG10 to TTR. Remarkably, similar hydrogen bonds have been reported within the inner cavity of the kinetically stabilizing trans-suppressor T119M-TTR variant (<a href="#F3" class="usa-link">Figure 3b</a>).<sup><a href="#R22" class="usa-link" aria-describedby="R22">22</a>, <a href="#R23" class="usa-link" aria-describedby="R23">23</a></sup></p>
<figure class="fig xbox font-sm" id="F3"><h4 class="obj_head">Figure 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6276790_nihms-996579-f0004.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595e/6276790/8b362c7c78d5/nihms-996579-f0004.jpg" loading="lazy" height="380" width="800" alt="Figure 3."></a></p>
<div class="p text-right font-secondary"><a href="figure/F3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p id="P67">Crystal structures highlighting similar interactions caused by the T119M mutation and binding of AG10 to TTR. (a) Quaternary structure of AG10 bound to V122I-TTR (PDB: 4HIQ)<sup><a href="#R15" class="usa-link" aria-describedby="R15">15</a></sup> shown as a ribbon representation with monomers colored individually. Close-up views of one of the two identical T<sub>4</sub> binding sites with different colored ribbons for the two monomers of the tetramer composing the binding site. Key hydrogen bonds between the pyrazole ring of AG10 and S117/117’ are highlighted by dashed lines. (b) Crystal structure of the stabilizing T119M-TTR variant (PDB: 1FHN)<sup><a href="#R22" class="usa-link" aria-describedby="R22">22</a></sup> with dashed lines highlighting key interactions between the hydroxyl groups of S117 and S117’. (c) Crystal structure of TTRwt (PDB: 3CFM).<sup><a href="#R26" class="usa-link" aria-describedby="R26">26</a></sup> (d) Crystal structure of thermodynamically stabilized R104H-TTR (PDB: 1X7T).<sup><a href="#R27" class="usa-link" aria-describedby="R27">27</a></sup></p></figcaption></figure><p id="P14">The two S117 side chain hydroxyl groups of monomers A and B in T119M variant TTR form direct hydrogen bonds with a distance of 2.8 Å, which are not observed in TTRwt (distance between the two S117 residues ~6.0 Å) (<a href="#F3" class="usa-link">Figure 3c</a>). These unique hydrogen bonds lead to closer contacts between the two dimers (~4.8 Å) within the TTR tetramer and highlight the potential importance of these hydrogen bonds in the anti-amyloidosis and disease-protective effects of the T119M variant on the TTR tetramers. The role of S117 in stabilizing TTR has been also suggested by the binding of flavonoids that are capable of forming a single hydrogen bond with one S117.<sup><a href="#R24" class="usa-link" aria-describedby="R24">24</a>, <a href="#R25" class="usa-link" aria-describedby="R25">25</a></sup> Interestingly, the distance between the S117 and S117’ residues in the thermodynamically stabilized R104H variant, which does not involve kinetic stabilization of the tetrameric TTR, is similar to that of TTRwt (average dimer—dimer distance is ~5.6 Å, <a href="#F3" class="usa-link">Figure 3c,d</a>).<sup><a href="#R26" class="usa-link" aria-describedby="R26">26</a>, <a href="#R27" class="usa-link" aria-describedby="R27">27</a></sup> The lack of hydrogen bonding between the hydroxyl groups of S117 and S117’ in the R104H variant (which is a less potent trans-suppressor mutant than T119M) highlights the importance of these hydrogen bonds in the anti-amyloidogenic and disease suppressing effects of kinetically stabilizing the TTR tetramer in the T119M variant. By forming two direct hydrogen bonds with S117 and S117’ in the TTR tetramer, AG10 creates a similar electrostatic bridge as is found in the protective T119M variant. This data is supported by the analysis of 40 reported crystal structures which highlighted the closer dimer—dimer contacts in the crystal structures of both T119M-TTR (distance ~4.8 Å) and AG10—V122I-TTR (distance ~4.66 Å) compared to TTRwt or TTRm (distance ~5.5 Å) (<a href="#SD1" class="usa-link">Supplementary Table 1</a>). It is important to note that other known TTR stabilizers do not interact with S117/S117’ of TTR.</p></section><section id="S6"><h3 class="pmc_sec_title">Characterization of key functional groups of AG10 important for TTR Stabilization.</h3>
<p id="P15">In order to investigate the enthalpic contribution of each of the functional groups of AG10 on TTR binding and stabilization, we synthesized and tested four AG10 analogues (compounds <strong>1</strong>, <strong>2</strong>, <strong>3</strong>, and <strong>4</strong>; <a href="#F8" class="usa-link">Scheme 1</a>) and evaluated their ability to bind and stabilize TTR (<a href="#F4" class="usa-link">Figure 4</a>). AG10 binds TTR with unfavorable entropy (<em>T</em>Δ<em>S</em> = −2.26 kcal/mol). The fluorine atom of AG10 is placed into HBP1 of TTR and therefore we hypothesized that the entropic binding of AG10 to TTR could be optimized by replacing the fluorine atom of AG10 with an iodine (compound <strong>1</strong>). Modeling studies suggest the iodine of <strong>1</strong> fits in HBP1 of TTR (where the iodine of T4 binds) which could improve the entropic binding by displacing more water molecules from HBP1 (<a href="#F4" class="usa-link">Figure 4a</a>). Compound <strong>1</strong> displayed significantly lower binding affinity (<em>K</em><sub>d</sub> = 90 ± 14 nM) to TTR in buffer compared to AG10 (<em>K</em><sub>d</sub> = 4.8 ± 1.9 nM). ITC analysis showed that while the entropic interaction of <strong>1</strong> with TTR was more favorable compared to AG10 (<em>T</em>Δ<em>S</em> = −0.21 kcal/mol and −2.26 kcal/mol, respectively), there was a significant drop in the enthalpic contribution to the binding (Δ<em>H</em> = −9.82 kcal/mol and −13.6 kcal/mol, respectively) (<a href="#F4" class="usa-link">Figure 4b</a>). As suggested by modeling, the decrease in binding enthalpy could be explained by the decrease in strength of the salt bridge between the carboxylic acid moiety of <strong>1</strong> and K15/K15’ (distance ~4.7 Å compared to ~2.8 Å for AG10). Compound <strong>1</strong> also displayed reduced potency for TTR in buffer (58.3 ± 0.98%) and human serum (75.9 ± 3.1%) compared to AG10 (<a href="#F4" class="usa-link">Figure 4c–e</a> and <a href="#T1" class="usa-link">Table 1</a>).</p>
<figure class="fig xbox font-sm" id="F8"><h4 class="obj_head">Scheme 1:</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6276790_nihms-996579-f0009.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595e/6276790/32e38cc44115/nihms-996579-f0009.jpg" loading="lazy" height="673" width="800" alt="Scheme 1:"></a></p>
<div class="p text-right font-secondary"><a href="figure/F8/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p id="P72">synthesis of AG10 analogues <strong>1</strong>, <strong>2</strong>, <strong>3</strong>, and <strong>4</strong>. a) <strong>5a</strong> i. acetylacetone, DBU, benzene, rt, 3 days; ii. hydrazine hydrate, ethanol, 90°C, 4 h; iii. NaOH, MeOH/water, 50°C, 14 h; b) <strong>5b</strong>, i. acetylacetone, DBU, benzene, rt, 3 days; ii. hydrate, ethanol, 90°C, 4 h; c) 1. NaH, Mel, DMF. rt, 12 hr; ii. NaOH/water, 50°C, 14 h; d <strong>5b</strong>, i. 3,5-Heptanedione, DBU, benzene, rt, 3 days; ii. hydrazine hydrate, ethanol, 90°C, 4 h; e) NaOH, MeOH/water, 50°C, 14 h.</p></figcaption></figure><figure class="fig xbox font-sm" id="F4"><h4 class="obj_head">Figure 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6276790_nihms-996579-f0005.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595e/6276790/d1025e2d6ecd/nihms-996579-f0005.jpg" loading="lazy" height="944" width="975" alt="Figure 4."></a></p>
<div class="p text-right font-secondary"><a href="figure/F4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p id="P68">The hydrogen bonds between the pyrazole ring of AG10 and S117/S117’ of TTR are important for effective binding to TTR. (a) Chemical structures and <em>in silico</em> docking study of synthesized AG10 analogues <strong>1</strong>, <strong>2</strong>, <strong>3</strong>, and <strong>4</strong>. Co-crystal structure of AG10 bound to TTR used for the docking experiment. <strong>1</strong> is the iodo-analogue of AG10. <strong>2</strong> is the methyl-ester form of AG10 that cannot form salt bridge with K15/15’. <strong>3</strong> is the methyl-pyrazole form of AG10 that can potentially form only one hydrogen bond with either K15 or K15’. <strong>4</strong> is the diethyl-pyrazole analogue of AG10 which affects both hydrogen bonds with S117/S117’. (b) Interaction of TTR with analogues assessed by ITC. Thermodynamic data; ΔG are blue bars, ΔH are green bars, and -TΔS are red bars. (c) Fluorescence change caused by modification of TTR in buffer (2.5 μM) by FPE probe monitored in the presence of probe alone (Control DMSO) or TTR stabilizers (2.5 μM; 1:1 Stabilizers to TTR ratio). (d) Bar graph representation of percent occupancy of TTR in buffer by stabilizers in the presence of FPE probe measured after 3 hr of incubation relative to probe alone. Error bars indicate SD (n = 3). (e) Bar graph representation of Western blot data for the stabilization of TTR in human serum by analogues (10 μM; 2:1 Stabilizers to TTR ratio). Error bars indicate SD (n = 4). The significance of the differences were measured by one-way ANOVA followed by Tukey’s multiple comparison test (n.s., not significant; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001)</p></figcaption></figure><p id="P16">The carboxylic acid moiety of AG10 forms two salt bridges directly with the ɛ-amino groups of K15 and K15′ at the periphery of the T<sub>4</sub>-binding site which serve to close the T<sub>4</sub> pocket around AG10 and partially shield it from the solvent. We synthesized a methyl-ester analogue of AG10 (compound <strong>2</strong>, <a href="#F4" class="usa-link">Figure 4a</a>) to test the effect of modifying the two salt bridges that AG10 forms at the periphery of the T<sub>4</sub>-binding site. Compound <strong>2</strong> displayed significantly lower affinity (<em>K</em><sub>d</sub> = 258 ± 17 nM) to TTR in buffer compared to AG10 (<em>K</em><sub>d</sub> = 4.8 ± 1.9 nM), which could be explained by the lower strength of potential hydrogen bonds between the ester group of <strong>2</strong> and K15/K15’ (Δ<em>H</em> = −6.49 kcal/mol) compared to the salt bridge in AG10 (<a href="#F4" class="usa-link">Figure 4b</a>). Compound <strong>2</strong> also displayed reduced potency for TTR in buffer and human serum compared to AG10 and compound <strong>1</strong> (<a href="#F4" class="usa-link">Figure 4c–e</a> and <a href="#T1" class="usa-link">Table 1</a>).</p>
<p id="P17">The 3,5-dimethyl-1<em>H</em>-pyrazole ring of AG10 sits deep within the inner cavity of the T<sub>4</sub>-binding site, and forms two hydrogen bonds with the S117 and S117′ of adjacent subunits.<sup><a href="#R15" class="usa-link" aria-describedby="R15">15</a></sup> By blocking these interactions, we can effectively observe their enthalpic contribution using ITC and the FPE assay, respectively. Therefore, we synthesized compound <strong>3</strong> which has an N-methyl pyrazole. The N-methyl group would restrict the pyrazole ring of <strong>3</strong> to form only one hydrogen bond with one of the adjacent TTR subunits (<a href="#F4" class="usa-link">Figure 4a</a>). We also synthesized compound <strong>4</strong> where the dimethyl pyrazole of AG10 was replaced with diethyl pyrazole. Modeling studies suggested that the bulk of the diethyl groups would prevent the molecules for reaching deep in the T<sub>4</sub>-binding site, thereby decreasing its ability to potentially form any hydrogen bonds with S117/S117’ (<a href="#F4" class="usa-link">Figure 4a</a>). As predicted by modeling, both <strong>3</strong> (<em>K</em><sub>d</sub> = 251 ± 12 nM) and <strong>4</strong> (<em>K</em><sub>d</sub> = 1253 ± 79 nM) showed greatly reduced binding affinity to TTR in buffer. This reduced affinity was translated into a significant decrease in potency for TTR in buffer and human serum, especially for compound <strong>4</strong>. The order of potency for stabilizing TTR was similar in both buffer and serum (<strong>1</strong> &gt; <strong>2</strong> &gt; <strong>3</strong> &gt; <strong>4</strong>; <a href="#F4" class="usa-link">Figure 4c–e</a> and <a href="#T1" class="usa-link">Table 1</a>). As we observed with the clinical ATTR stabilizers, the potency of AG10 and compounds <strong>1</strong>, <strong>2</strong>, <strong>3</strong>, and <strong>4</strong> in occupying and stabilizing TTR correlated very well (<em>R</em><sup><em>2</em></sup> = 0.98) with the binding enthalpy of these molecules (Δ<em>H</em> = −13.6, −9.82, −6.49, −4.73, and −2.1 kcal/mol, respectively). Interestingly, despite the similar binding affinities of <strong>2</strong> and <strong>3</strong>, their potency was significantly different (<a href="#T1" class="usa-link">Table 1</a>). The higher potency of <strong>2</strong> compared to <strong>3</strong> could be explained by its favorable enthalpic binding (Δ<em>H</em> = −6.49 kcal/mol and −4.73 kcal/mol, respectively) (<a href="#F4" class="usa-link">Figure 4b</a>). This observation is similar to the data obtained for AG10 and tafamidis (i.e. similar <em>K</em><sub>d</sub> values but significantly different potency) (<a href="#T1" class="usa-link">Table 1</a>). These results highlight the crucial role played by the pyrazole ring and the importance of the hydrogen bonds it forms with the two TTR dimers, mimicking the interactions in the protective T119M-TTR mutation, and enhancing the kinetic stability of the TTR tetramer.</p></section><section id="S7"><h3 class="pmc_sec_title">Examining the effect of enthalpy on the selectivity of AG10 to TTR.</h3>
<p id="P18">To examine the role of enthalpy on the selectivity of AG10 for TTR over other abundant serum proteins, we tested the concentration-effect relationship of AG10 and tafamidis in the FPE assay in whole human serum (<a href="#SD1" class="usa-link">Supplementary Figure 4a,b</a>). We tested AG10 and tafamidis since their binding affinities for TTR in buffer is very similar (<em>K</em><sub>d</sub> = 4.8 ± 1.9 nM and 4.4 ± 1.3 nM, respectively) but their thermodynamics for binding TTR, especially the enthalpy component, is significantly different. Therefore, the data obtained in serum would largely reflect selectivity. AG10 displayed a progressive concentration-dependent occupancy, with complete occupancy achieved at AG10 concentrations ≥ 10 μM. Even at sub-stoichiometric concentrations, AG10 was able to occupy and stabilize the majority of TTR (at 5 μM, TTR occupancy of 69.2% by FPE, 74.5% stabilization by Western blot). In contrast, there was a more modest increment in either occupancy or stabilizing activity of tafamidis at concentrations above 20 μM (<a href="#SD1" class="usa-link">Supplementary Figure 4b,c</a>). A good correlation (<em>R</em><sup><em>2</em></sup> = 1.0) between TTR occupancy (by FPE) and TTR stabilization (by Western blot) was observed when the activity of AG10 was evaluated (<a href="#SD1" class="usa-link">Supplementary Figure 5a,b</a>). For tafamidis, there was a good correlation (<em>R</em><sup><em>2</em></sup> = 0.87) for concentrations up to 10 μM, however, at higher concentrations there was a plateau in the FPE assay (<a href="#SD1" class="usa-link">Supplementary Figure 5c,d</a>).</p>
<p id="P19">The selectivity of AG10 and tafamidis for TTR was further investigated by repeating these assays in buffer in the presence or absence of purified serum proteins. AG10 or tafamidis (30 μM) were pre-incubated with purified human serum albumin (at its physiological concentration of 600 μM) and then subjected to gel filtration followed by dialysis. At time 0 (immediately after gel filtration), less AG10 was bound to albumin compared to tafamidis (18.3 ± 0.98 μM vs. 24.1 ± 1.1 μM; <a href="#F5" class="usa-link">Figure 5a</a>). Following dialysis vs buffer for 24 hr, the concentration of AG10 bound to HSA was lower than that for tafamidis (7.8 ± 0.1 μM vs. 18.8 ± 2.1 μM). These data indicate that AG10 has a lower binding affinity for albumin compared to tafamidis. In parallel the binding of AG10 to TTR was also investigated in this gel filtration/dialysis assay. AG10 (10 μM) was pre-incubated with an equimolar ratio TTR (5 μM of tetrameric TTR, representing 10 μM of TTR T4 binding sites). The dissociation of AG10 from TTR was slow for the first six hours (AG10-TTR molar ratio of ~1.2:1), and maintained a 1:1 molar ratio over a 24 hr incubation (<a href="#F5" class="usa-link">Figure 5b</a>).</p>
<figure class="fig xbox font-sm" id="F5"><h4 class="obj_head">Figure 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6276790_nihms-996579-f0006.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595e/6276790/e3246876c64e/nihms-996579-f0006.jpg" loading="lazy" height="847" width="800" alt="Figure 5."></a></p>
<div class="p text-right font-secondary"><a href="figure/F5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p id="P69">AG10 has high selectivity for binding TTR over albumin or other abundant human serum proteins. (a) Gel filtration and dialysis assay comparing AG10 and tafamidis (each at 30 μM) incubated with purified human serum albumin (600 μM). The concentration of tafamidis bound to albumin after gel-filtration (i.e. dialysis time 0 hr) was normalized to 100%. Error bars indicate SD (n = 3). (b) 24 hr time-course for dialysis of AG10 (10 μM) incubated with purified human TTR (5 μM). Error bars indicate SD (n = 3). (c) Fluorescence change due to modification of purified human TTR (5 μM) by FPE probe monitored for 6 hr in the presence of probe alone (black circles), probe plus albumin (600 μM) (black triangles), probe plus all [fibrinogen (5 μM), albumin (600 μM), IgG (70 μM), transferrin (25 μM)] (grey triangles); probe and AG10 (10 μM) (red squares) or probe and AG10 plus albumin (green diamonds), probe and AG10 plus all [fibrinogen (5 μM), albumin (600 μM) IgG (70 μM), transferrin (25 μM)] (blue circles). (d) %TTR occupancy in buffer by AG10 in the presence of FPE probe and other serum proteins measured after 3 hr of incubation relative to probe alone. (e, f) Same experiment described for AG10 was performed for tafamidis. Error bars indicate SD (n = 3). The significance of the differences were measured by one-way ANOVA followed by Tukey’s multiple comparison test (n.s., not significant; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001)</p></figcaption></figure><p id="P20">Finally, the selectivity of AG10 and tafamidis for binding to TTR in human serum was evaluated using a modified FPE assay where human serum was replaced with purified human TTR in buffer (PBS buffer, pH 7.4). In addition to purified TTR (5 μM), four separate representative and abundant plasma proteins were added to the FPE assay in buffer. Addition of albumin, transferrin, fibrinogen or immunoglobulin (IgG) did not influence TTR occupancy by AG10 (&gt;97% TTR occupancy in the absence or presence of any of these proteins, <a href="#F5" class="usa-link">Figure 5c,d</a>). Albumin, but not the other serum proteins tested, interfered with TTR occupancy by tafamidis (41.5 ± 0.9% vs. 68.2 ± 0.1% in the absence of albumin; <a href="#F5" class="usa-link">Figure 5e,f</a>). Adding all of the tested plasma proteins simultaneously yielded identical results for AG10. The higher selectivity of AG10 for TTR could be attributed to a number of properties, including the enthalpic binding and greater hydrophilicity of AG10 (ClogP = 2.78) compared to the more lipophilic tafamidis (ClogP = 4.2).</p></section><section id="S8"><h3 class="pmc_sec_title">Healthy Beagle Dog is a Suitable Experimental Model for Evaluating the Efficacy of TTR Stabilizers.</h3>
<p id="P21">We then investigated if the high potency and selectivity of AG10 for TTR can be maintained <em>in vivo</em>. Transgenic animal models that faithfully reproduce the pathology of human ATTR-CM are not yet available. Therefore, we took an approach similar to that currently used in the clinic to examine the efficacy of AG10 vs other TTR kinetic stabilizers. The activity of TTR stabilizers in occupying and stabilizing TTR is commonly assessed <em>ex vivo</em> in blood samples obtained from patients before and after dosing of the stabilizer. To explore the <em>in vivo</em> activity of AG10, this same approach was used in the healthy beagle dog. The healthy beagle dog was chosen as an experimental model for several reasons. All amino acids in the T4 binding sites of TTR, where AG10 and other stabilizers bind, are conserved between dog and human.<sup><a href="#R28" class="usa-link" aria-describedby="R28">28</a></sup> We also tested the concentration of TTR in dog serum (~4.6 μM) and found it similar to that of healthy humans (<a href="#SD1" class="usa-link">Supplementary Figure 6</a>).</p>
<p id="P22">To confirm the suitability of assays used with human-based reagents for dog studies, the activity of AG10 and tafamidis was evaluated in pooled dog serum using the same FPE and Western blot assays used for the experiments described above. The <em>in vitro</em> TTR binding and stabilization concentration-effect relationships of AG10 and tafamidis in both assays repeated using dog serum was similar to those observed in human serum (<a href="#F6" class="usa-link">Figure 6</a>). These features made the healthy canine a suitable system for subsequent investigations.</p>
<figure class="fig xbox font-sm" id="F6"><h4 class="obj_head">Figure 6.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6276790_nihms-996579-f0007.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595e/6276790/4aab7b207c14/nihms-996579-f0007.jpg" loading="lazy" height="576" width="800" alt="Figure 6."></a></p>
<div class="p text-right font-secondary"><a href="figure/F6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p id="P70">Activity of AG10 and tafamidis in the FPE and Western blot assays performed with pooled dog serum. (a) Fluorescence change caused by modification of dog TTR in commercially available beagle dog serum by FPE probe monitored in the presence of probe alone (Control DMSO, black circles), AG10 (10 μM) or tafamidis (10 μM). (b) Percent occupancy of dog TTR in dog serum by AG10 and tafamidis in the presence of FPE probe measured after 3 hr of incubation relative to probe alone. Error bars indicate SD (n = 4). (c) Western blot image for the stabilization of TTR in pooled dog serum against acid-mediated denaturation in the presence of AG10 (10 μM) and tafamidis (10 μM). Serum samples were incubated with DMSO or test compounds in acetate buffer (pH 4.0) for the desired time period (0 and 72 h) before crosslinking and immunoblotting. (d) Bar graph representation of stabilization data obtained from Western blot experiments. Error bars indicate SD (n = 3). The significance of the differences were measured by one-way ANOVA followed by Tukey’s multiple comparison test (n.s., not significant; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001)</p></figcaption></figure></section><section id="S9"><h3 class="pmc_sec_title">AG10 Potently and Selectively Binds to Canine TTR Following Oral Administration.</h3>
<p id="P23">To explore the pharmacokinetic-pharmacodynamic (PK-PD) relationship <em>in vivo</em>, AG10 was administered to healthy beagle dogs daily by oral gavage for 7 days. A total of 16 male (M) and 16 female (F) beagle dogs made up four treatment groups: (i) 6M/6F at 0 mg/kg/d (vehicle control); (ii) 2M/2F at 50 mg/kg/d; (iii) 2M/2F at 100 mg/kg/d; and (iv) 6M/6F at 200 mg/kg/d. Timed serum samples were collected pre-dose on study day 1 (baseline), pre-dose on study day 7 (representing trough concentrations, or C<sub>min</sub>, at steady state), and at 1 hr post-dose on study day 7 (representing peak concentrations, or C<sub>max</sub>, at steady state). Binding occupancy of TTR by AG10 was assessed by FPE assay (<a href="#F7" class="usa-link">Figure 7a,b</a>). All samples from dogs treated with vehicle alone, and those collected from the active treatment arms prior to exposure to AG10, showed zero TTR occupancy. Serum from AG10-treated dogs displayed a dose-proportional response in binding occupancy at the steady state trough (day 7 pre-dose; ~81–94% TTR occupancy), and all AG10 treated groups showed complete (&gt;97%) TTR occupancy at steady state C<sub>max</sub> (day 7 post-dose). Lower doses of AG10 were subsequently tested to further explore the PK-PD (exposure-effect) relationship in order to identify a minimally effective dose of AG10 that might still effectively bind to and stabilize TTR. Eight dogs divided into two active treatment groups received either 5 or 20 mg/kg AG10 as a single oral dose. These results showed enhanced TTR occupancy in the 20 mg/kg vs. 5 mg/kg dose groups (<a href="#F7" class="usa-link">Figure 7c,d</a> and <a href="#SD1" class="usa-link">Supplementary Figure 7</a>). The %TTR occupancy at C<sub>max</sub> was significantly higher (p ≤ 0.001) than at C<sub>min</sub> for both doses. There was significantly higher (p ≤ 0.001) TTR occupancy for the 20 mg/kg dose compared to the 5 mg/kg dose at C<sub>min</sub>. The data also showed that circulating plasma concentration of AG10 correlates well with %TTR occupancy.</p>
<figure class="fig xbox font-sm" id="F7"><h4 class="obj_head">Figure 7.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=6276790_nihms-996579-f0008.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595e/6276790/d70842c9c331/nihms-996579-f0008.jpg" loading="lazy" height="573" width="800" alt="Figure 7."></a></p>
<div class="p text-right font-secondary"><a href="figure/F7/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p id="P71">Orally administered AG10 is effective in binding and stabilizing TTR in dogs. (a and b) Occupancy of TTR in beagle dogs after oral administration (q.d. for 7 days) of escalating doses of AG10. Circles (●) indicate pre-dose day 1, squares (■) indicate pre-dose day 7 (AG10 concentration at C<sub>min</sub>), and triangles (▲) indicate post-dose day 7 (AG10 concentration at C<sub>max</sub>). Four groups of animals were dosed: (i) 0 mg/kg (n=12, 6 males/6 females); (ii) 50 mg/kg (n=4, 2 males/2 females); (iii) 100 mg/kg (n=4, 2 males/2 females); (iv) 200 mg/kg (n=12, 6 males/6 females) (b) Bar graph representing TTR occupancy at 3 hr. Error bars indicate SD (n = 3). (c and d) Pharmacokinetic-Pharmacodynamic (PK-PD) analysis of AG10 in dogs receiving a single oral dose of AG10 at (c) 5 mg/kg and (d) 20 mg/kg. Scatterplot of concentration [AG10] vs. %TTR occupancy of serum samples obtained from dogs at various time points (n=4, 2 males/2 females per dosing group). Error bars indicate SD (n = 3). The significance of the differences were measured by one-way ANOVA followed by Tukey’s multiple comparison test (n.s., not significant; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001).</p></figcaption></figure></section></section><section id="S10"><h2 class="pmc_sec_title">DISCUSSION</h2>
<p id="P24">Optimizing the binding enthalpy of small molecules has been associated with the development of second-generation drugs with improved selectivity.<sup><a href="#R16" class="usa-link" aria-describedby="R16">16</a>, <a href="#R17" class="usa-link" aria-describedby="R17">17</a>, <a href="#R29" class="usa-link" aria-describedby="R29">29</a></sup> Enthalpic forces have also been correlated with the stability of protein association complexes.<sup><a href="#R30" class="usa-link" aria-describedby="R30">30</a>, <a href="#R31" class="usa-link" aria-describedby="R31">31</a></sup> However, the effect of the enthalpic component of binding of a small-molecule on its potency in stabilizing multimeric proteins has not been reported. In order to account for structural features important for effective TTR stabilization, we compared the TTR binding and stabilizing activity of four ATTR clinical candidates and four AG10 analogues. We found that the <em>K</em><sub>d</sub> between a stabilizer and TTR does not by itself correlate well with either potency or selectivity (<a href="#T1" class="usa-link">Table 1</a>). Our results suggest that enthalpic forces, in combination with <em>K</em><sub>d</sub> measurements in a purified protein, are better predictors of both potency and selectivity for stabilizing TTR in serum.</p>
<p id="P25">The trans-suppressor T119M-TTR is a super-stabilizing variant compared to TTRwt (reported T119M-TTR dissociation rate is 40-fold slower than that of TTRwt).<sup><a href="#R9" class="usa-link" aria-describedby="R9">9</a></sup> This variant effectively ameliorates disease progression and symptoms in compound heterozygous individuals carrying the pathogenic, destabilizing V30M mutation.<sup><a href="#R12" class="usa-link" aria-describedby="R12">12</a></sup> The T119M substitution induces conformational changes that promote hydrogen bonding between the hydroxyl groups of adjacent S117 residues of T119M-TTR monomers and lead to closer contacts between the two dimers within the tetramer.<sup><a href="#R22" class="usa-link" aria-describedby="R22">22</a></sup> These enthalpically favorable interactions and their consequences are neither observed in TTRwt nor in the thermodynamically stabilized, disease-protective R104H variant, suggesting that they are important for the enhanced kinetic stabilization of the TTR tetramer. Our studies show that AG10’s enthalpically-driven mode of action is through kinetic stabilization of TTR, which is similar to the kinetically stabilizing T119M variant and not comparable to the thermodynamically stabilizing R104H. When comparing the T119M mutation to the co-crystal structure of AG10 bound to the kinetically destabilized V122I-TTR, the similarities of these critical intramolecular interactions are evident and we conclude that AG10’s mode of binding, especially the two hydrogen bonds with S117/S117’ that are buried in the low dielectric macromolecular interior of the T4 pocket, may well explain AG10’s efficient binding and stabilizing of tetrameric TTR. The experiments comparing closely related, structural analogues of AG10 highlight the important role of the pyrazole ring of AG10 in enthalpically driving the binding by forming two hydrogen bonds with different subunits of TTR. These unique interactions with the S117/S117’ residues at the bottom of the T4 binding pocket of TTR are not observed in other stabilizers. To the best of our knowledge, this is the first report describing a correlation between enthalpic binding of a ligand and enhanced potency in stabilizing multi-protein complexes.</p>
<p id="P26">Similar to T119M-TTR, enthalpic forces have been reported to play a dominant role in stabilizing the eye lens crystallin proteins. Analysis of the association energetics of β-crystallins (which associate into dimers, tetramers, and higher order oligomers) showed that β-crystallins which associate by predominately hydrophobic forces participate in a weaker protein associations whereas the formation of stable tetramers is dominated by enthalpically-driven interactions between the subunits (mediated by hydrogen bonds, salt bridges, and van der Waals interactions).<sup><a href="#R32" class="usa-link" aria-describedby="R32">32</a></sup> Hereditary cataracts are caused by mutations that destabilize the crystallin proteins, leading to the assembly of crystallins into amyloid-like fibers. For example, the R120G mutation in αB-crystallin disrupts ionic interactions that normally stabilize the αB-crystallin dimer (wild type αB-crystallin dimer is stabilized by a salt bridge between R120 and D109).<sup><a href="#R33" class="usa-link" aria-describedby="R33">33</a></sup> These studies with TTR (where the introduction of an enthalpic interaction in the T119M variant hyper-stabilize the tetramer) and crystallins (where disrupting an enthalpic interaction in the R120G variant destabilizes the dimer) suggest that enthalpic forces controlling protein association could be similar to forces influencing effective protein stabilization by small molecules such as AG10. This hypothesis would be further supported by additional site-directed mutagenesis and structural studies to investigate if factors other than enthalpy are also involved in the enhanced stabilization of TTR.</p></section><section id="S11"><h2 class="pmc_sec_title">CONCLUSIONS</h2>
<p id="P27">In summary, we have developed a pre-clinical <em>in vivo</em> approach to evaluate the efficacy of TTR stabilizers. Beagle dogs demonstrated that AG10 is orally available, and achieves dose-dependent plasma concentrations that potently and selectively bind and stabilize tetrameric TTR. The similarity between dog and human TTR, and the expected similarity in PK behavior of many small molecules between dog and human, suggest that these data can serve as a guide for selecting a dosing regimen for stabilizers to attain safe and effective TTR binding and stabilization in ATTR-CM patients. By analyzing the molecular interactions that stabilizers form with TTR and comparing it to interactions within stabilizing TTR mutations, we suggest that electrostatic interactions formed deep in the T4 site of TTR (which could be similar to the hydrogen bonds between S117/117’ of T119M-TTR and between the pyrazole of AG10 and TTR) are more effective in stabilizing TTR compared to hydrophobic interaction and interactions at the solvent exposed portion of the T4 pocket. There are limited examples where the binding of a small molecule to a known disease-causing target mimics a stabilizing mutation identified in that target protein.<sup><a href="#R34" class="usa-link" aria-describedby="R34">34</a></sup> In addition to stabilizing TTR, we hypothesize that molecules with similar enthalpically-driven binding mode to that of AG10 could be useful in stabilizing multi-subunit protein complexes in certain diseases such as crystallins in cataract and α-synuclein tetramer in Parkinson’s Disease.<sup><a href="#R35" class="usa-link" aria-describedby="R35">35</a>, <a href="#R36" class="usa-link" aria-describedby="R36">36</a></sup></p></section><section id="S12"><h2 class="pmc_sec_title">EXPERIMENTAL SECTION</h2>
<section id="S13"><h3 class="pmc_sec_title">Experimental Animals.</h3>
<p id="P28">All experiments with male and female beagle dogs were conducted in accordance with National Institutes of Health guidelines for the care and use of live animals and were approved by the Institutional Animal Care and Use Committee of Covance and PreClinical Research Services.</p></section><section id="S14"><h3 class="pmc_sec_title">Isothermal Titration Calorimetry (ITC).</h3>
<p id="P29">Binding experiments were performed using MicroCal PEAQ-ITC at 25 °C. A solution of ligand (25 μM in PBS pH 7.4, 100 mM KCl, 1 mM EDTA, 2.5% DMSO) was prepared and titrated into an ITC cell containing 2 μM of TTR in an identical buffer. 19 injections of ligand (2.0 μL each) were injected into the ITC cell (at 25<sup>o</sup>C) to the point that TTR was fully saturated with ligand. Calorimetric data were plotted and fitted using the standard single-site binding model. For control, we tested the enthalpy change caused by titrating bank DMSO in buffer into TTR and the resulting binding enthalpies was &lt; 0.4 kcal/mol. We also used ITC to titrate tafamidis and AG10 against human serum albumin (HSA). The <em>K</em><sub>d</sub> value for tafamidis (2.3 μM) was similar to what has been reported earlier (<em>K</em><sub>d</sub> = 2.5 μM; EMA Assesment Report EMA/729083/2011). The binding affinity of AG10 was calculated around 8 μM, which also fits with our data in <a href="#F5" class="usa-link">Figure 5</a> (where AG10 has lower binding to albumin compared to tafamidis).</p></section><section id="S15"><h3 class="pmc_sec_title">FPE assay for binding TTR in buffer and human or dog serum.</h3>
<p id="P30">The binding affinity and selectivity of AG10 and other stabilizers to TTR in buffer and serum was determined by their ability to compete with the binding of a fluorescent probe exclusion (FPE probe) binding to TTR in buffer and human serum.<sup><a href="#R18" class="usa-link" aria-describedby="R18">18</a></sup> The FPE probe is a thioester TTR ligand (<a href="#SD1" class="usa-link">Supplementary Figure 1</a>) that is not fluorescent by itself, however upon binding to the T4 binding site of TTR it covalently modifies lysine 15 (K15), creating a fluorescent conjugate. Ligands that bind to the T4 site of TTR will decrease FPE probe binding as observed by lower fluorescence. The FPE assay was also adapted for use with dog serum. <em>FPE with TTR in buffer:</em> An aliquot of 98 μL of TTR in PBS (pH 7.4, final concentration: 2.5 μM) was mixed with 1 μL of test compounds (2.5 μM) and 1 μL of FPE probe (0.18 mM stock solution in DMSO: final concentration: 1.8 μM). The change in fluorescence (λ<sub>ex</sub> = 328 nm and λ<sub>em</sub> = 384 nm) were monitored using a microplate spectrophotometer reader (SpectraMax M5) for 6 hr at rt. <em>FPE with TTR in human and dog serumr:</em> An aliquot of 98 μL of pooled human serum (prepared from human male AB plasma, Sigma; catalog no. H4522; TTR concentration 5 μM) or dog serum (Innovative Research, catalog no.: IBG-SER; TTR concentration 4.6 μM) was mixed with 1 μL of test compounds [All compounds were prepared as 10 mM stock solutions in DMSO and diluted accordingly with DMSO (final concentrations in serum were: AG10 10 μM; diflunisal 200 μM; tafamidis 20 μM; tolcapone 20 μM)] and 1 μL of FPE probe (0.36 mM stock solution in DMSO: final concentration: 3.6 μM). In the case of dog serum (after oral treatment with AG10), 1 μL of FPE probe and 1 μL of DMSO were added to each well and mixed with 98 μL of the appropriate dog serum sample. The change in fluorescence (λ<sub>ex</sub> = 328 nm and λ<sub>em</sub> = 384 nm) were monitored using a microplate spectrophotometer reader (SpectraMax M5) for 6 hr at rt.</p></section><section id="S16"><h3 class="pmc_sec_title">Stability studies of TTR in serum by immunoblotting.</h3>
<p id="P31">Western blotting was performed as reported earlier.<sup><a href="#R15" class="usa-link" aria-describedby="R15">15</a>, <a href="#R37" class="usa-link" aria-describedby="R37">37</a></sup> All compounds were prepared as 10 mM stock solutions in DMSO and diluted accordingly with DMSO (final concentrations in serum were: AG10 10 μM; diflunisal 200 μM; tafamidis 20 μM; tolcapone 20 μM). 2 μL of each compound was added to 98 μL of human serum (TTR concentration 5 μM). The samples were incubated at 37°C for 2 hr, and then 10 μL of the samples were diluted 1:10 with acidification buffer (pH 4.0, 100 mM sodium acetate, 100 mM KCl, 1 mM EDTA, 1 mM DTT). The Western blot assay was also performed in Urea buffer (pH 7.4) as reported earlier.<sup><a href="#R19" class="usa-link" aria-describedby="R19">19</a></sup> The samples were incubated at room temperature for 72 hr, cross-linked with glutaraldehyde (final concentration of 2.5%) for 5 min, and then quenched with 10 μL of 7% sodium borohydride solution in 0.1 M NaOH. All samples were denatured by adding 100 μL SDS gel loading buffer and boiled for 5 min. 10 μL of each sample was separated in 12% SDS-PAGE gel and analyzed by immunoblotting using anti-TTR antiserum (DAKO A0002, 1:10,000 dilution for human serum and 1:2,000 for dog serum). The combined intensity of TTR bands (TTR tetramer and tetramer bound to RBP) was quantified by using an Odyssey IR imaging system (LI-COR Bioscience) and reported as percentage of TTR tetramer relative to TTR tetramer density of DMSO control at 0 hr (considered 100% stabilization) and 72 hr (ranges between 10% and 35% TTR remaining). The percentage tetramer stabilization is calculated as 100 × [(tetramer and tetramer + RBP density, 72 hr)/(tetramer and tetramer + RBP density of DMSO, 0 hr)].</p></section><section id="S17"><h3 class="pmc_sec_title">
<em>In silico</em> structural and modeling studies.</h3>
<p id="P32">The analyses of the crystal structures of TTR were carried out on four TTR crystal structures obtained from the RCSB PDB site. Biological assemblies of TTR tetramers were constructed using the X-ray crystallographic unit cell information given in the pdb files. When multiple models are suggested, the first choice model was used. The initial geometries of the AG10 and its four derivatives (<strong>1</strong>, <strong>2</strong>, <strong>3</strong>, and <strong>4</strong>) built with Molden<sup><a href="#R38" class="usa-link" aria-describedby="R38">38</a></sup> were used and geometry optimizations were carried out at the hybrid density functional B3LYP level with 6–311+G(d) basis set using Gaussian’09 program package (<em>Wallingford, CT, USA: Gaussian, Inc.</em>, 2009). The Frequency calculations on the optimized geometries were carried out to ensure they have no imaginary frequencies. Dock 6 program was used for the docking experiments. The crystal structure of the V122I mutant TTR complex with AG10 (pdb id: 4HIQ)<sup><a href="#R15" class="usa-link" aria-describedby="R15">15</a></sup> was used as the receptor. Tetrameric TTR was built using the crystallographic data, solvent and other hetero-atoms were removed and one large docking grid was selected including the T4 binding sites. For all the docking experiments, the same receptor and the grid were used. The flexible ligand docking was carried out to allow the rotation around the torsion angles. UCSF Chimera package was used in visualization and analyses of the 3D structures.<sup><a href="#R39" class="usa-link" aria-describedby="R39">39</a></sup></p></section><section id="S18"><h3 class="pmc_sec_title">Binding of AG10 and tafamidis to human serum albumin.</h3>
<p id="P33">Test compounds (AG10 or tafamidis; both at 30 μM) were incubated with human serum albumin (HSA; 600 μM; albumin from human serum; Sigma Aldrich, catalog no.: A3782) in assay buffer (10 mM sodium phosphate, 100 mM KCl, and 1 mM EDTA, pH 7.6) for 1 hr at 37<sup>o</sup>C. 500 μL of a solution of HSA and AG10 or tafamidis mixture in assay buffer was subjected to gel filtration on PD Minitrap G25 columns (GE Life Sciences, catalog no. 45-001-529) by gravity and the fractions containing HSA were identified by NanoDrop™. The concentration of HSA (i.e. concentration at time zero) was also determined using NanoDrop™ (based on calibration curves of known HSA concentrations). HSA concentration was 351 μM for the tafamidis sample and 345 μM for AG10 sample. The concentration of test compounds in these fractions (i.e. conc. at time zero) was evaluated using HPLC (based on calibration curves of known concentration of test compounds). 500 μL of each HSA/test compound samples was then added to a Slide-A-Lyzer Dialysis Cassette G2 (3.5K MWCO, Thermo Scientific, catalog no. PI87722). The dialysis Cassettes were placed in 100 ml of assay buffer and stirred at room temperature. After 24 hr, the samples were removed from dialysis cassette and the volume was measured. The concentration of HSA and test compounds were determined using NanoDrop™ and HPLC as described above.</p></section><section id="S19"><h3 class="pmc_sec_title">Dialysis of AG10:TTR complex.</h3>
<p id="P34">AG10 (10 μM) was incubated with human wild-type TTR (5 μM; purified from human plasma; Sigma Aldrich, catalog no. P1742) in assay buffer (10 mM sodium phosphate, 100 mM KCl, and 1 mM EDTA, pH 7.6) for 1 hr at 37<sup>o</sup>C. 500 μL of each AG10/TTR solution was then added to a Slide-A-Lyzer Dialysis cassette G2. The dialysis cassettes were placed in 100 mL of assay buffer and stirred at room temperature. Samples from the dialysis buffer were taken at different time points (0, 0.5, 1, 2, 6, and 24 hr). After 24 hr, the samples were removed from dialysis cassette and the volume was measured and results normalized. The concentration of TTR and AG10 obtained from the assay buffer were determined using NanoDrop™ and LCMS, respectively.</p></section><section id="S20"><h3 class="pmc_sec_title">Selectivity of AG10 and tafamidis to TTR compared to other serum proteins.</h3>
<p id="P35">The FPE assay was modified and performed with purified human TTRwt (5 μM). Other serum proteins were added either individually or in combination [fibrinogen (5 μM), albumin (600 μM), IgG (70 μM), transferrin (25 μM)] to the TTR and FPE mixture and the fluorescence was monitored for 6 hr as described above. The percentage of FPE probe binding to TTR in the presence of serum proteins measured after 3 hr of incubation was used to calculate % TTR occupancy.</p></section><section id="S21"><h3 class="pmc_sec_title">7-day repeat oral dosing of AG10 to dogs.</h3>
<p id="P36">16 Male (M) and 16 female (F) beagle dogs, separated into four treatment groups and orally dosed by gavage with vehicle (6M/6F at 0 mg/kg) or AG10 in 0.5% methylcellulose formulation (2M/2F at 50 mg/kg, 2M/2F at 100 mg/kg, and 6M/6F at 200 mg/kg) for a total of 32 dogs. Blood (approximately 1.5 mL) was collected from a jugular vein into serum separator tubes on study day 1 (predose D1), pre-dose study day 7 (predose D7), and at 1 hr post-dose study day 7 (postdose D7). These serum samples were analyzed for their TTR occupancy using the FPE assay described above.</p></section><section id="S22"><h3 class="pmc_sec_title">Single oral doses of AG10 to dogs to determine an exposure-effect (PK-PD) relationship with respect to binding to and stabilization of TTR.</h3>
<p id="P37">4 Male and 4 female beagle dogs, separated into two treatment groups (n=2/sex/group) for a total of 8 dogs were evaluated to acquire simultaneous pharmacokinetic (PK) and pharmacodynamic (PD) data for AG10 binding to and stabilization of TTR. Each animal received a single oral gavage (PO) of AG10 at a single dose of either 5 or 20 mg/kg in 0.5% methylcellulose. Blood was collected and analyzed pre-dose and at 2, 4, 6, 8, 12 and 24 hr post-dose. The concentration of AG10 in these serum samples was analyzed by LCMS and the TTR occupancy by the FPE assay.</p></section><section id="S23"><h3 class="pmc_sec_title">Statistical Analysis.</h3>
<p id="P38">All results are expressed as mean±SD,. All statistical analysis was performed with GraphPad PRISM software. The significance of the differences were measured by one-way ANOVA followed by Tukey’s multiple comparison test (n.s., not significant; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001).</p></section><section id="S24"><h3 class="pmc_sec_title">Chemistry. General.</h3>
<p id="P39">All reactions were carried out under argon atmosphere using dry solvents under anhydrous conditions, unless otherwise noted. The solvents used were ACS grade from Fisher. Reagents were purchased from Aldrich and Fisher, and used without further purification. Reactions were monitored by thin-layer chromatography (TLC) carried out on 0.20 mm POLYGRAM® SIL silica gel plates (Art.-Nr. 805 023) with fluorescent indicator UV254 using UV light as a visualizing agent. Normal phase flash column chromatography was carried out using Davisil® silica gel (100–200 mesh, Fisher). <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Jeol JNM−ECA600 spectrometer and calibrated using residual undeuterated solvent as an internal reference. Coupling constants (J) were expressed in Hertz. The following abbreviations were used to explain the multiplicities: s = singlet, d = doublet, t =triplet, q = quartet, m = multiplet. High-resolution mass spectra (HRMS) were recorded by JEOL DART AccuTOF (Direct Analysis in Real Time). HPLC analysis was performed on Agilent 1100 series HPLC system connected to a diode array detector operating between the UV ranges of 200 – 400 nm and quantified using Agilent Chemstation software. The HPLC analysis was performed on both Waters™ XBridge C18 column with L1 packing (4.6 × 250 mm, 5μm) and SymmetricTM C4 (2.1 × 150 mm, 5μm) at ambient temperature upon injection of a 50 μl of each Blank buffer, standard and/or sample to obtain the chromatogram. The mobile phase was composed of solvent A consisting methanol-water (5:95, v/v) containing 0.1 % formic acid and solvent B consisting methanol-water (95:5, v/v) containing 0.1 % formic acid. The HPLC program was a gradient separation method increasing linearly from 0 % to 100 % solvent B from 0 to 20 min and then maintained 100 % solvent B up to 30 min.</p></section><section id="S25"><h3 class="pmc_sec_title">Key Compounds Purity:</h3>
<p id="P40">HPLC analysis was performed on both C18 and C4 reversed-phase columns. The purity for all key compounds was &gt;95%. Description of the purity analysis has been included in the experimental section. Detailed HPLC information of key compounds (traces, retention times, and %Purity) are included in the supplementary information of the revised manuscript.</p></section><section id="S26"><h3 class="pmc_sec_title">Synthetic Procedures.</h3>
<p id="P41">AG10 and tafamidis were synthesized as reported earlier.<sup><a href="#R15" class="usa-link" aria-describedby="R15">15</a></sup> Tolcapone and Diflunisal were purchased from Fisher. All AG10 analogues were prepared as described below.</p></section><section id="S27"><h3 class="pmc_sec_title">3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-iodobenzoic acid (1);</h3>
<p id="P42">A solution of methyl 3-(3-bromopropoxy)-4-Iodobenzoate (<strong>5a</strong>)<sup><a href="#R15" class="usa-link" aria-describedby="R15">15</a></sup> (834 mg, 2.1 mmol, 1 equiv) in benzene (3 ml) was added dropwise to a solution of acetyl acetone (0.43 ml, 4.2 mmol, 2 equiv) and DBU (0.627 ml, 4.2 mmol, 2 equiv) in benzene (7 ml). The reaction mixture was stirred at room temperature for 3 days. The mixture was filtered and concentrated. To a solution of this intermediate in ethanol (5 ml) was added hydrazine hydrate (0.28 ml, 5.25 mmol, 2.5 equiv) and the reaction was heated under reflux for 4 hr. The reaction was concentrated and purified by flash column chromatography (silica gel, 1–20% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford the methyl ester of compound <strong>1</strong>; Sodium hydroxide (79 mg, 1.98 mmol, 2 equiv) in water (2.5 ml) was added to a solution of ester intermediate (412 mg, 0.99 mmol) in methanol (10 ml) and the reaction was heated under reflux for 4 hr (50°C). The reaction was concentrated and purified by flash column chromatography (silica gel, 1–5% MeOH/EtOAc) to afford compound <strong>1</strong> (183 mg, 22% yield for three steps); (98.3% purity by HPLC): t<sub>R</sub> (column) (C18) = 25.72min; t<sub>R</sub> (C4) = 16.06 min.<sup>1</sup> H NMR (CD<sub>3</sub>OD, 600 MHz) δ 7.86 (d, 1H, J = 8.4 Hz), 7.41 (d, 1H, J = 1.2 Hz), 7.34 (dd, 1H, J = 1.2 Hz and 8.4 Hz), 4.0 (t, 2H, J = 6.0 Hz), 2.67 (t, 2H, J = 7.2 Hz), 2.13 (s, 6H), 1.97–1.93 (m, 2H). <sup>13</sup>C NMR (CD<sub>3</sub>OD, 600 MHz) δ 168.5, 157.6, 142, 139.2, 133.2, 123.1, 114, 117.8, 91.7, 67.5, 29.6, 18.7, 9.3; (HRMS (DART) m/z: calcd for C<sub>15</sub>H<sub>17</sub>IN<sub>2</sub>O<sub>3</sub> + H<sup>+</sup> 401.0362; found 401.0347 (M+H<sup>+</sup>).</p></section><section id="S28"><h3 class="pmc_sec_title">Methyl 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoate (2);</h3>
<p id="P43">A solution of methyl 3-(3-bromopropoxy)-4-fluorobenzoate (<strong>5b</strong>)<sup><a href="#R15" class="usa-link" aria-describedby="R15">15</a></sup> (780 mg, 2.69 mmol, 1 equiv) in benzene (3 ml) was added dropwise to a solution of acetyl acetone (0.552 ml, 5.38 mmol, 2 equiv) and DBU (0.804 ml, 5.38 mmol, 2 equiv) in benzene (7 ml). The reaction mixture was stirred at room temperature for 3 days. The mixture was filtered and concentrated. The residue was purified by flash column chromatography (silica gel, 1–10% EtOAc/hexanes) to afford the alkylated intermediate which was used in the next step directly. To a solution of this intermediate in ethanol (5 ml) was added hydrazine hydrate (0.36 ml, 6.73 mmol, 2.5 equiv) and the reaction was heated under reflux for 4 hr. The reaction was concentrated and purified by flash column chromatography (silica gel, 1–20% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford compound <strong>2</strong> (288 mg, 35% yield); (96.3% purity by HPLC): t<sub>R</sub> (column) (C18) = 25.11 min; t<sub>R</sub> (C4) = 14.03 min. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 600 MHz) δ 7.63–7.58 (m, 2H), 7.19–7.15 (m, 1H), 4.00 (t, 2H, J = 6.0 Hz), 3.86 (s, 3H), 2.58 (t, 2H, J = 7.2 Hz), 2.12 (s, 6H), 1.97–1.92 (m, 2H). <sup>13</sup>C NMR (CD<sub>3</sub>OD, 600 MHz) δ 168.1, 158.4, 156.7, 148.9, 128.5, 124.6, 117.6, 117.0, 115.6, 69.4, 53.3, 31.1, 20.2, 10.9; HRMS (DART) m/z: calcd for C<sub>16</sub>H<sub>19</sub>FN<sub>2</sub>O<sub>3</sub> + H<sup>+</sup> 307.1458; found 307.1463 (M+H<sup>+</sup>).</p></section><section id="S29"><h3 class="pmc_sec_title">4-fluoro-3-(3-(1,3,5-trimethyl-1H-pyrazol-4-yl)propoxy)benzoic acid (3):</h3>
<p id="P44">A solution of <strong>2</strong> (21 mg, 0.07 mmol, 1 equiv) in DMF (3 ml) was added sodium hydride (5 mg, 0.21 mmol, 3 equiv) and methyl iodide (17 μl, 0.28 mmol, 4 equiv). The reaction mixture was stirred at room temperature for 2 hr. The mixture was extracted with brine, filtered and concentrated. The residue was purified by flash column chromatography (silica gel, 0.5–2% MeOH/EtOAc) to afford the alkylated intermediate which was used in the next step directly. Sodium hydroxide (5.6 mg, 0.14 mmol, 2 equiv) in water (0.5 ml) was added to a solution of alkylated intermediate in methanol (2 ml) and the reaction was heated under reflux for 4 hr (50°C). The reaction was concentrated and purified by flash column chromatography (silica gel, 1–5% MeOH/EtOAc) to afford compound <strong>3</strong> (11 mg, 52% yield for two steps); (97.8% purity by HPLC): t<sub>R</sub> (column) (C18) = 25.25 min; t<sub>R</sub> (C4) = 15.71 min.<sup>1</sup> H NMR (CD<sub>3</sub>OD, 600 MHz) δ 7.58–7.51 (m, 2H), 7.10–7.06 (m, 1H), 3.92 (t, 2H, J = 6.0 Hz), 3.56 (s, 3H), 2.49 (t, 2H, J = 7.2 Hz), 2.05 (s, 3H), 2.01 (s, 3H), 1.83–1.88 (m, 2H). <sup>13</sup>C NMR (CD<sub>3</sub>OD, 600 MHz) δ 168.1, 154.6, 146.8, 145.3, 137.2, 128.1, 122.8, 115.5, 115.4, 114.8, 67.4, 34.3, 29.4, 18.8, 10.1, 7.9; HRMS (DART) m/z: calcd for C<sub>16</sub>H<sub>19</sub>FN<sub>2</sub>O<sub>3</sub> + H<sup>+</sup> 307.1458; found 307.1449 (M+H<sup>+</sup>).</p></section><section id="S30"><h3 class="pmc_sec_title">3-(3-(3,5-diethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid (4):</h3>
<p id="P45">Sodium hydroxide (3.2 mg, 0.08 mmol, 2 equiv) in water (0.5 ml) was added to a solution of <strong>6</strong> (13 mg, 0.04 mmol, 1 equiv) in methanol (2 ml) and the reaction was heated under reflux for 4 hr (50°C). The reaction was concentrated and purified by flash column chromatography (silica gel, 1–5% MeOH/EtOAc) to afford compound <strong>4</strong> (10 mg, 80% yield); (96.0% purity by HPLC): t<sub>R</sub> (column) (C18) = 25.16 min; t<sub>R</sub> (C4) = 15.56 min. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 600 MHz) δ 7.57–7.49 (m, 2H), 7.08–7.04 (m, 1H), 3.94 (t, 2H, J = 6.0 Hz), 2.51–2.43 (m, 6H), 1.87–1.82 (m, 2H), 1.06 (t, 6H, J=7.8 Hz). <sup>13</sup>C NMR (CD<sub>3</sub>OD, 600 MHz) δ 169.8, 157.9, 156.3, 149.3, 148.5, 124.6, 117.2, 117.1, 114.1, 69.4, 31.8, 20.1, 19.9, 14.7; HRMS (DART) m/z: calcd for C<sub>17</sub>H<sub>21</sub>FN<sub>2</sub>O<sub>3</sub> + H<sup>+</sup> 321.1614; found 321.1601 (M+H<sup>+</sup>).</p></section><section id="S31"><h3 class="pmc_sec_title">Methyl 3-(3-bromopropoxy)-4-fluorobenzoate (5):</h3>
<p id="P46">compound <strong>5</strong> was synthesized as reported earlier<sup><a href="#R15" class="usa-link" aria-describedby="R15">15</a></sup>. To a solution of methyl 4-fluoro-3hydroxybenzoate (1.0 g, 5.87 mmol, 1 equiv) and 1,3-dibromopropane (3.0 ml, 29.4 mmol, 5 equiv) in DMF (15 ml) was added K<sub>2</sub>CO3 (0.98 g, 7.1 mmol, 1.2 equiv). The reaction mixture was stirred at room temperature for 16 hours. The mixture was diluted with EtOAc (500 ml), washed with brine (3×200 ml) and dried with Na<sub>2</sub>SO<sub>4</sub>. The solution was filtered and concentrated. The residue was purified by flash column chromatography (silica gel, 1–10% EtOAc/hexanes) to afford compound 5 (1.3 g, 76% yield); <sup>1</sup>H NMR (CD<sub>3</sub>OD, 600 MHz) δ 7.67–7.61 (m, 2H), 7.14–7.07 (m, 1H), 4.21 (t, 2H, J = 5.89 Hz), 3.89 (s, 3H), 3.62 (t, 2H, J = 6.38 Hz), 2.38–2.31 (m, 2H); (ESI+) m/z: calcd for C<sub>11</sub>H<sub>12</sub>BrFO<sub>3</sub> + H<sup>+</sup> 290.00; found 290.01 (M + H<sup>+</sup>).</p></section><section id="S32"><h3 class="pmc_sec_title">Methyl 3-(3-(3,5-diethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoate (6):</h3>
<p id="P47">A solution of <strong>5b</strong> (100 mg, 0.35 mmol, 1 equiv) in benzene (2 ml) was added dropwise to a solution of 3,5-heptanedione (0.095 ml, 0.7 mmol, 2 equiv) and DBU (0.104 ml, 0.7 mmol, 2 equiv) in benzene (5 ml). The reaction mixture was stirred at room temperature for 3 days. The mixture was filtered and concentrated. The residue was purified by flash column chromatography (silica gel, 1–10% EtOAc/hexanes) to afford the alkylated intermediate which was used in the next step directly. Hydrazine hydrate (0.047ml, 0.875 mmol, 2.5 equiv) was added to the alkylated intermediate in ethanol (4 ml) and the reaction was heated under reflux for 4 hr. The reaction was concentrated and purified by flash column chromatography (silica gel, 1–5% MeOH/EtOAc) to afford compound <strong>6</strong> (75 mg, 65% yield for two steps); <sup>1</sup> H NMR (CD<sub>3</sub>OD, 600 MHz) δ 7.59–7.54 (m, 2H), 7.15–7.11 (m, 1H), 3.98 (t, 2H, J = 6.0 Hz), 3.81 (s, 3H), 2.56–2.47 (m, 6H), 1.91–1.86 (m, 2H), 1.13 (t, 6H, J=7.8 Hz). <sup>13</sup>C NMR (CD<sub>3</sub>OD, 600 MHz) δ 167.9, 156.6, 156.2, 148.8, 148.7, 124.4, 117.5, 117.3, 116.9, 113.9, 69.5, 53.1, 31.8, 20.1, 14.7; HRMS (DART) m/z: calcd for C<sub>18</sub>H<sub>23</sub>FN<sub>2</sub>O<sub>3</sub> + H<sup>+</sup> 335.1771; found 335.1773 (M+H<sup>+</sup>).</p></section></section><section id="SM1"><h2 class="pmc_sec_title">Supplementary Material</h2>
<section class="sm xbox font-sm" id="SD1"><div class="caption p"><span>supplemental materials</span></div>
<div class="media p" id="d36e1653"><div class="caption">
<a href="/articles/instance/6276790/bin/NIHMS996579-supplement-supplemental_materials.pdf" data-ga-action="click_feat_suppl" class="usa-link">NIHMS996579-supplement-supplemental_materials.pdf</a><sup> (907.8KB, pdf) </sup>
</div></div></section></section><section id="S33" class="ack"><h2 class="pmc_sec_title">ACKNOWLEDGMENTS</h2>
<p id="P48">This work was supported by the National Institutes of Health grant 1R15GM110677–01 (M.A.) and Eidos Therapeutics. The support by a National Science Foundation Instrumentation grant (NSF-MRI-0722654) is gratefully acknowledged. Thanks to Vyacheslav Samoshin and Andreas Franz for NMR and mass spec analysis.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">ABBREVIATIONS USED</h2>
<dl class="def-list">
<dt>TTR</dt>
<dd><p id="P52">transthyretin</p></dd>
<dt>ATTR</dt>
<dd><p id="P53">transthyretin amyloidosis</p></dd>
<dt>ATTR-CM</dt>
<dd><p id="P54">transthyretin amyloid cardiomyopathy</p></dd>
<dt>TTRm</dt>
<dd><p id="P55">transthyretin mutations</p></dd>
<dt>TTRwt</dt>
<dd><p id="P56">wild type transthyretin</p></dd>
<dt>ATTRm-CM</dt>
<dd><p id="P57">familial transthyretin amyloid cardiomyopathy</p></dd>
<dt>ATTRwt-CM</dt>
<dd><p id="P58">wild type transthyretin amyloid cardiomyopathy</p></dd>
<dt>ATTR-PN</dt>
<dd><p id="P59">transthyretin peripheral polyneuropathy</p></dd>
<dt>T4</dt>
<dd><p id="P60">thyroxine</p></dd>
<dt>ITC</dt>
<dd><p id="P61">isothermal titration calorimetry</p></dd>
<dt>NSAIDs</dt>
<dd><p id="P62">nonsteroidal anti-inflammatory drugs</p></dd>
<dt>FPE assay</dt>
<dd><p id="P63">fluorescence probe exclusion assay</p></dd>
<dt>PK-PD</dt>
<dd><p id="P64">pharmacokinetic-pharmacodynamic</p></dd>
</dl></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="FN3"><p id="P49">Supporting Information: Supplementary Table 1; Supplementary Figures 1–7; and HPLC analysis of AG10, tafamidis, diflunisal, tolcapone and AG10 analogues 1, 2, 3, and 4; Molecular Formula Strings of key compounds.</p></div>
<div class="fn p" id="FN4">
<p id="P50">Notes</p>
<p id="P51">The authors declare the following competing financial interest(s): Authors M.A. and I.G. are cofounders of Eidos Therapeutics. R.Z, N.K., J.F., and U.S. are employees of Eidos Therapeutics. The remaining authors declare noncompeting financial interests.</p>
</div>
</div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">REFERENCES</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="R1">
<span class="label">1.</span><cite>Falk RH; Comenzo RL; Skinner M
The systemic amyloidoses. N Engl J Med
1997, 337, 898–909.</cite> [<a href="https://doi.org/10.1056/NEJM199709253371306" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9302305/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=The%20systemic%20amyloidoses&amp;author=RH%20Falk&amp;author=RL%20Comenzo&amp;author=M%20Skinner&amp;volume=337&amp;publication_year=1997&amp;pages=898-909&amp;pmid=9302305&amp;doi=10.1056/NEJM199709253371306&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R2">
<span class="label">2.</span><cite>Johnson SM; Wiseman RL; Sekijima Y; Green NS; Adamski-Werner SL; Kelly JW
Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res
2005, 38, 911–921.</cite> [<a href="https://doi.org/10.1021/ar020073i" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16359163/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acc%20Chem%20Res&amp;title=Native%20state%20kinetic%20stabilization%20as%20a%20strategy%20to%20ameliorate%20protein%20misfolding%20diseases:%20a%20focus%20on%20the%20transthyretin%20amyloidoses&amp;author=SM%20Johnson&amp;author=RL%20Wiseman&amp;author=Y%20Sekijima&amp;author=NS%20Green&amp;author=SL%20Adamski-Werner&amp;volume=38&amp;publication_year=2005&amp;pages=911-921&amp;pmid=16359163&amp;doi=10.1021/ar020073i&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R3">
<span class="label">3.</span><cite>Brunjes DL; Castano A; Clemons A; Rubin J; Maurer MS
Transthyretin Cardiac Amyloidosis in Older Americans. J Card Fail
2016, 22, 996–1003.</cite> [<a href="https://doi.org/10.1016/j.cardfail.2016.10.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5127719/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27769906/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Card%20Fail&amp;title=Transthyretin%20Cardiac%20Amyloidosis%20in%20Older%20Americans&amp;author=DL%20Brunjes&amp;author=A%20Castano&amp;author=A%20Clemons&amp;author=J%20Rubin&amp;author=MS%20Maurer&amp;volume=22&amp;publication_year=2016&amp;pages=996-1003&amp;pmid=27769906&amp;doi=10.1016/j.cardfail.2016.10.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R4">
<span class="label">4.</span><cite>Ton VK; Mukherjee M; Judge DP
Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction. Clin Med Insights Cardiol
2014, 8, 39–44.</cite> [<a href="https://doi.org/10.4137/CMC.S15719" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4284988/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25628512/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Med%20Insights%20Cardiol&amp;title=Transthyretin%20cardiac%20amyloidosis:%20pathogenesis,%20treatments,%20and%20emerging%20role%20in%20heart%20failure%20with%20preserved%20ejection%20fraction&amp;author=VK%20Ton&amp;author=M%20Mukherjee&amp;author=DP%20Judge&amp;volume=8&amp;publication_year=2014&amp;pages=39-44&amp;pmid=25628512&amp;doi=10.4137/CMC.S15719&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R5">
<span class="label">5.</span><cite>Buxbaum JN; Ruberg FL
Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genet Med
2017, 19, 733–742.</cite> [<a href="https://doi.org/10.1038/gim.2016.200" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5509498/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28102864/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genet%20Med&amp;title=Transthyretin%20V122I%20(pV142I)*%20cardiac%20amyloidosis:%20an%20age-dependent%20autosomal%20dominant%20cardiomyopathy%20too%20common%20to%20be%20overlooked%20as%20a%20cause%20of%20significant%20heart%20disease%20in%20elderly%20African%20Americans&amp;author=JN%20Buxbaum&amp;author=FL%20Ruberg&amp;volume=19&amp;publication_year=2017&amp;pages=733-742&amp;pmid=28102864&amp;doi=10.1038/gim.2016.200&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R6">
<span class="label">6.</span><cite>Alexander KM; Falk RH
V122I TTR Cardiac Amyloidosis in Patients of African Descent: Recognizing a Missed Disease or the Dog That Didn’t Bark?
Circ Heart Fail
2016, 9, 1–2.</cite> [<a href="https://doi.org/10.1161/CIRCHEARTFAILURE.116.003489" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27618856/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circ%20Heart%20Fail&amp;title=V122I%20TTR%20Cardiac%20Amyloidosis%20in%20Patients%20of%20African%20Descent:%20Recognizing%20a%20Missed%20Disease%20or%20the%20Dog%20That%20Didn%E2%80%99t%20Bark?&amp;author=KM%20Alexander&amp;author=RH%20Falk&amp;volume=9&amp;publication_year=2016&amp;pages=1-2&amp;pmid=27618856&amp;doi=10.1161/CIRCHEARTFAILURE.116.003489&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R7">
<span class="label">7.</span><cite>Connors LH; Doros G; Sam F; Badiee A; Seldin DC; Skinner M
Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy. Amyloid
2011, 18
Suppl 1, 152–154.</cite> [<a href="https://doi.org/10.3109/13506129.2011.574354059" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5603797/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21838471/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Clinical%20features%20and%20survival%20in%20senile%20systemic%20amyloidosis:%20comparison%20to%20familial%20transthyretin%20cardiomyopathy&amp;author=LH%20Connors&amp;author=G%20Doros&amp;author=F%20Sam&amp;author=A%20Badiee&amp;author=DC%20Seldin&amp;volume=18&amp;issue=Suppl%201&amp;publication_year=2011&amp;pages=152-154&amp;pmid=21838471&amp;doi=10.3109/13506129.2011.574354059&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R8">
<span class="label">8.</span><cite>Connors LH; Lim A; Prokaeva T; Roskens VA; Costello CE
Tabulation of human transthyretin (TTR) variants, 2003. Amyloid
2003, 10, 160–184.</cite> [<a href="https://doi.org/10.3109/13506120308998998" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14640030/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Tabulation%20of%20human%20transthyretin%20(TTR)%20variants,%202003&amp;author=LH%20Connors&amp;author=A%20Lim&amp;author=T%20Prokaeva&amp;author=VA%20Roskens&amp;author=CE%20Costello&amp;volume=10&amp;publication_year=2003&amp;pages=160-184&amp;pmid=14640030&amp;doi=10.3109/13506120308998998&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R9">
<span class="label">9.</span><cite>Hammarström P; Jiang X; Hurshman AR; Powers ET; Kelly JW
Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc Natl Acad Sci U S A
2002, 99
Suppl 4, 16427–16432.</cite> [<a href="https://doi.org/10.1073/pnas.202495199" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC139904/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12351683/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;title=Sequence-dependent%20denaturation%20energetics:%20A%20major%20determinant%20in%20amyloid%20disease%20diversity&amp;author=P%20Hammarstr%C3%B6m&amp;author=X%20Jiang&amp;author=AR%20Hurshman&amp;author=ET%20Powers&amp;author=JW%20Kelly&amp;volume=99&amp;issue=Suppl%204&amp;publication_year=2002&amp;pages=16427-16432&amp;pmid=12351683&amp;doi=10.1073/pnas.202495199&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R10">
<span class="label">10.</span><cite>Adams D; Théaudin M; Cauquil C; Algalarrondo V; Slama M
FAP neuropathy and emerging treatments. Curr Neurol Neurosci Rep
2014, 14, 435,  1–12.</cite> [<a href="https://doi.org/10.1007/s11910-013-0435-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24482069/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Neurol%20Neurosci%20Rep&amp;title=FAP%20neuropathy%20and%20emerging%20treatments&amp;author=D%20Adams&amp;author=M%20Th%C3%A9audin&amp;author=C%20Cauquil&amp;author=V%20Algalarrondo&amp;author=M%20Slama&amp;volume=14&amp;publication_year=2014&amp;pages=435-12&amp;pmid=24482069&amp;doi=10.1007/s11910-013-0435-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R11">
<span class="label">11.</span><cite>Sekijima Y; Dendle MT; Wiseman RL; White JT; D’Haeze W; Kelly JW
R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression. Amyloid
2006, 13, 57–66.</cite> [<a href="https://doi.org/10.1080/13506120600722449" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16911959/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=R104H%20may%20suppress%20transthyretin%20amyloidogenesis%20by%20thermodynamic%20stabilization,%20but%20not%20by%20the%20kinetic%20mechanism%20characterizing%20T119%20interallelic%20trans-suppression&amp;author=Y%20Sekijima&amp;author=MT%20Dendle&amp;author=RL%20Wiseman&amp;author=JT%20White&amp;author=W%20D%E2%80%99Haeze&amp;volume=13&amp;publication_year=2006&amp;pages=57-66&amp;pmid=16911959&amp;doi=10.1080/13506120600722449&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R12">
<span class="label">12.</span><cite>Coelho T; Sousa R; Alves I; Torres MF; Saraiva M
Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathy. Neuromuscul Disord
1996, 6, S20.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Neuromuscul%20Disord&amp;title=Compound%20heterozygotes%20of%20transthyretin%20Met30%20and%20transthyretin%20Met119%20are%20protected%20from%20the%20devastating%20effects%20of%20familial%20amyloid%20polyneuropathy&amp;author=T%20Coelho&amp;author=R%20Sousa&amp;author=I%20Alves&amp;author=MF%20Torres&amp;author=M%20Saraiva&amp;volume=6&amp;publication_year=1996&amp;pages=S20&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R13">
<span class="label">13.</span><cite>Hornstrup LS; Frikke-Schmidt R; Nordestgaard BG; Tybjærg-Hansen A
Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy. Arterioscler Thromb Vasc Biol
2013, 33, 1441–1447.</cite> [<a href="https://doi.org/10.1161/ATVBAHA.113.301273" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23580146/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arterioscler%20Thromb%20Vasc%20Biol&amp;title=Genetic%20stabilization%20of%20transthyretin,%20cerebrovascular%20disease,%20and%20life%20expectancy&amp;author=LS%20Hornstrup&amp;author=R%20Frikke-Schmidt&amp;author=BG%20Nordestgaard&amp;author=A%20Tybj%C3%A6rg-Hansen&amp;volume=33&amp;publication_year=2013&amp;pages=1441-1447&amp;pmid=23580146&amp;doi=10.1161/ATVBAHA.113.301273&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R14">
<span class="label">14.</span><cite>Terazaki H; Ando Y; Misumi S; Nakamura M; Ando E; Matsunaga N; Shoji S; Okuyama M; Ideta H; Nakagawa K; Ishizaki T; Ando M; Saraiva MJ
A novel compound heterozygote (FAP ATTR Arg104His/ATTR Val30Met) with high serum transthyretin (TTR) and retinol binding protein (RBP) levels. Biochem Biophys Res Commun
1999, 264, 365–370.</cite> [<a href="https://doi.org/10.1006/bbrc.1999.1514" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10529370/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochem%20Biophys%20Res%20Commun&amp;title=A%20novel%20compound%20heterozygote%20(FAP%20ATTR%20Arg104His/ATTR%20Val30Met)%20with%20high%20serum%20transthyretin%20(TTR)%20and%20retinol%20binding%20protein%20(RBP)%20levels&amp;author=H%20Terazaki&amp;author=Y%20Ando&amp;author=S%20Misumi&amp;author=M%20Nakamura&amp;author=E%20Ando&amp;volume=264&amp;publication_year=1999&amp;pages=365-370&amp;pmid=10529370&amp;doi=10.1006/bbrc.1999.1514&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R15">
<span class="label">15.</span><cite>Penchala SC; Connelly S; Wang Y; Park MS; Zhao L; Baranczak A; Rappley I; Vogel H; Liedtke M; Witteles RM; Powers ET; Reixach N; Chan WK; Wilson IA; Kelly JW; Graef IA; Alhamadsheh MM
AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci U S A
2013, 110, 9992–9997.</cite> [<a href="https://doi.org/10.1073/pnas.1300761110" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3683741/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23716704/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;title=AG10%20inhibits%20amyloidogenesis%20and%20cellular%20toxicity%20of%20the%20familial%20amyloid%20cardiomyopathy-associated%20V122I%20transthyretin&amp;author=SC%20Penchala&amp;author=S%20Connelly&amp;author=Y%20Wang&amp;author=MS%20Park&amp;author=L%20Zhao&amp;volume=110&amp;publication_year=2013&amp;pages=9992-9997&amp;pmid=23716704&amp;doi=10.1073/pnas.1300761110&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R16">
<span class="label">16.</span><cite>Iakovleva I; Brännström K; Nilsson L; Gharibyan AL; Begum A; Anan I; Walfridsson M; Sauer-Eriksson AE; Olofsson A
Enthalpic Forces Correlate with the Selectivity of Transthyretin-Stabilizing Ligands in Human Plasma. J Med Chem
2015, 58, 6507–6515.</cite> [<a href="https://doi.org/10.1021/acs.jmedchem.5b00544" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26214366/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Med%20Chem&amp;title=Enthalpic%20Forces%20Correlate%20with%20the%20Selectivity%20of%20Transthyretin-Stabilizing%20Ligands%20in%20Human%20Plasma&amp;author=I%20Iakovleva&amp;author=K%20Br%C3%A4nnstr%C3%B6m&amp;author=L%20Nilsson&amp;author=AL%20Gharibyan&amp;author=A%20Begum&amp;volume=58&amp;publication_year=2015&amp;pages=6507-6515&amp;pmid=26214366&amp;doi=10.1021/acs.jmedchem.5b00544&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R17">
<span class="label">17.</span><cite>Freire E
Do enthalpy and entropy distinguish first in class from best in class?
Drug Discov Today
2008, 13, 869–874.</cite> [<a href="https://doi.org/10.1016/j.drudis2008.07.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2581116/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18703160/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drug%20Discov%20Today&amp;title=Do%20enthalpy%20and%20entropy%20distinguish%20first%20in%20class%20from%20best%20in%20class?&amp;author=E%20Freire&amp;volume=13&amp;publication_year=2008&amp;pages=869-874&amp;pmid=18703160&amp;doi=10.1016/j.drudis2008.07.005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R18">
<span class="label">18.</span><cite>Choi S; Kelly JW
A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin. Bioorg Med Chem
2011, 19, 1505–1514.</cite> [<a href="https://doi.org/10.1016/j.bmc.2010.12.050" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3039427/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21273081/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg%20Med%20Chem&amp;title=A%20competition%20assay%20to%20identify%20amyloidogenesis%20inhibitors%20by%20monitoring%20the%20fluorescence%20emitted%20by%20the%20covalent%20attachment%20of%20a%20stilbene%20derivative%20to%20transthyretin&amp;author=S%20Choi&amp;author=JW%20Kelly&amp;volume=19&amp;publication_year=2011&amp;pages=1505-1514&amp;pmid=21273081&amp;doi=10.1016/j.bmc.2010.12.050&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R19">
<span class="label">19.</span><cite>Bulawa CE; Connelly S; Devit M; Wang L; Weigel C; Fleming JA; Packman J; Powers ET; Wiseman RL; Foss TR; Wilson IA; Kelly JW; Labaudinière R
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A
2012, 109, 9629–9634.</cite> [<a href="https://doi.org/10.1073/pnas.1121005109" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3386102/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22645360/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;title=Tafamidis,%20a%20potent%20and%20selective%20transthyretin%20kinetic%20stabilizer%20that%20inhibits%20the%20amyloid%20cascade&amp;author=CE%20Bulawa&amp;author=S%20Connelly&amp;author=M%20Devit&amp;author=L%20Wang&amp;author=C%20Weigel&amp;volume=109&amp;publication_year=2012&amp;pages=9629-9634&amp;pmid=22645360&amp;doi=10.1073/pnas.1121005109&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R20">
<span class="label">20.</span><cite>Sant’Anna R; Gallego P; Robinson LZ; Pereira-Henriques A; Ferreira N; Pinheiro F; Esperante S; Pallares I; Huertas O; Almeida MR; Reixach N; Insa R; Velazquez-Campoy A; Reverter D; Reig N; Ventura S
Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat Commun
2016, 7, 10787,  1–13.</cite> [<a href="https://doi.org/10.1038/ncomms10787" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4766415/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26902880/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=Repositioning%20tolcapone%20as%20a%20potent%20inhibitor%20of%20transthyretin%20amyloidogenesis%20and%20associated%20cellular%20toxicity&amp;author=R%20Sant%E2%80%99Anna&amp;author=P%20Gallego&amp;author=LZ%20Robinson&amp;author=A%20Pereira-Henriques&amp;author=N%20Ferreira&amp;volume=7&amp;publication_year=2016&amp;pages=10787-13&amp;pmid=26902880&amp;doi=10.1038/ncomms10787&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R21">
<span class="label">21.</span><cite>Adamski-Werner SL; Palaninathan SK; Sacchettini JC; Kelly JW
Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem
2004, 47, 355–374.</cite> [<a href="https://doi.org/10.1021/jm030347n" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14711308/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Med%20Chem&amp;title=Diflunisal%20analogues%20stabilize%20the%20native%20state%20of%20transthyretin.%20Potent%20inhibition%20of%20amyloidogenesis&amp;author=SL%20Adamski-Werner&amp;author=SK%20Palaninathan&amp;author=JC%20Sacchettini&amp;author=JW%20Kelly&amp;volume=47&amp;publication_year=2004&amp;pages=355-374&amp;pmid=14711308&amp;doi=10.1021/jm030347n&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R22">
<span class="label">22.</span><cite>Sebastião MP; Lamzin V; Saraiva MJ; Damas AM
Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution. J Mol Biol
2001, 306, 733–744.</cite> [<a href="https://doi.org/10.1006/jmbi.2000.4415" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11243784/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Mol%20Biol&amp;title=Transthyretin%20stability%20as%20a%20key%20factor%20in%20amyloidogenesis:%20X-ray%20analysis%20at%20atomic%20resolution&amp;author=MP%20Sebasti%C3%A3o&amp;author=V%20Lamzin&amp;author=MJ%20Saraiva&amp;author=AM%20Damas&amp;volume=306&amp;publication_year=2001&amp;pages=733-744&amp;pmid=11243784&amp;doi=10.1006/jmbi.2000.4415&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R23">
<span class="label">23.</span><cite>Kim JH; Oroz J; Zweckstetter M
Structure of Monomeric Transthyretin Carrying the Clinically Important T119M Mutation. Angew Chem Int Ed Engl
2016, 55, 16168–16171.</cite> [<a href="https://doi.org/10.1002/anie.201608516" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27885756/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Angew%20Chem%20Int%20Ed%20Engl&amp;title=Structure%20of%20Monomeric%20Transthyretin%20Carrying%20the%20Clinically%20Important%20T119M%20Mutation&amp;author=JH%20Kim&amp;author=J%20Oroz&amp;author=M%20Zweckstetter&amp;volume=55&amp;publication_year=2016&amp;pages=16168-16171&amp;pmid=27885756&amp;doi=10.1002/anie.201608516&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R24">
<span class="label">24.</span><cite>Morais-de-Sá E; Pereira PJ; Saraiva MJ; Damas AM
The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors. J Biol Chem
2004, 279, 53483–53490.</cite> [<a href="https://doi.org/10.1074/jbc.M408053200" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15469931/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Biol%20Chem&amp;title=The%20crystal%20structure%20of%20transthyretin%20in%20complex%20with%20diethylstilbestrol:%20a%20promising%20template%20for%20the%20design%20of%20amyloid%20inhibitors&amp;author=E%20Morais-de-S%C3%A1&amp;author=PJ%20Pereira&amp;author=MJ%20Saraiva&amp;author=AM%20Damas&amp;volume=279&amp;publication_year=2004&amp;pages=53483-53490&amp;pmid=15469931&amp;doi=10.1074/jbc.M408053200&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R25">
<span class="label">25.</span><cite>Ortore G; Orlandini E; Braca A; Ciccone L; Rossello A; Martinelli A; Nencetti S
Targeting Different Transthyretin Binding Sites with Unusual Natural Compounds. ChemMedChem
2016, 11, 1865–1874.</cite> [<a href="https://doi.org/10.1002/cmdc.201600092" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27159149/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ChemMedChem&amp;title=Targeting%20Different%20Transthyretin%20Binding%20Sites%20with%20Unusual%20Natural%20Compounds&amp;author=G%20Ortore&amp;author=E%20Orlandini&amp;author=A%20Braca&amp;author=L%20Ciccone&amp;author=A%20Rossello&amp;volume=11&amp;publication_year=2016&amp;pages=1865-1874&amp;pmid=27159149&amp;doi=10.1002/cmdc.201600092&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R26">
<span class="label">26.</span><cite>Lima LM; Silva V. e. A.; Palmieri L. e. C.; Oliveira MC; Foguel D; Polikarpov I
Identification of a novel ligand binding motif in the transthyretin channel. Bioorg Med Chem
2010, 18, 100–110.</cite> [<a href="https://doi.org/10.1016/j.bmc.2009.11.025" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19954984/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg%20Med%20Chem&amp;title=Identification%20of%20a%20novel%20ligand%20binding%20motif%20in%20the%20transthyretin%20channel&amp;author=LM%20Lima&amp;author=V.%20e.%20A.%20Silva&amp;author=L.%20e.%20C.%20Palmieri&amp;author=MC%20Oliveira&amp;author=D%20Foguel&amp;volume=18&amp;publication_year=2010&amp;pages=100-110&amp;pmid=19954984&amp;doi=10.1016/j.bmc.2009.11.025&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R27">
<span class="label">27.</span><cite>Neto-Silva RM; Macedo-Ribeiro S; Pereira PJ; Coll M; Saraiva MJ; Damas AM
X-ray crystallographic studies of two transthyretin variants: further insights into amyloidogenesis. Acta Crystallogr D Biol Crystallogr
2005, 61, 333–339.</cite> [<a href="https://doi.org/10.1107/S0907444904034316" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15735344/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acta%20Crystallogr%20D%20Biol%20Crystallogr&amp;title=X-ray%20crystallographic%20studies%20of%20two%20transthyretin%20variants:%20further%20insights%20into%20amyloidogenesis&amp;author=RM%20Neto-Silva&amp;author=S%20Macedo-Ribeiro&amp;author=PJ%20Pereira&amp;author=M%20Coll&amp;author=MJ%20Saraiva&amp;volume=61&amp;publication_year=2005&amp;pages=333-339&amp;pmid=15735344&amp;doi=10.1107/S0907444904034316&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R28">
<span class="label">28.</span><cite>Fex G; Laurell CB; Thulin E
Purification of prealbumin from human and canine serum using a two-step affinity chromatographic procedure. Eur J Biochem
1977, 75, 181–186.</cite> [<a href="https://doi.org/10.1111/j.1432-1033.1977.tb11515.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/405214/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Biochem&amp;title=Purification%20of%20prealbumin%20from%20human%20and%20canine%20serum%20using%20a%20two-step%20affinity%20chromatographic%20procedure&amp;author=G%20Fex&amp;author=CB%20Laurell&amp;author=E%20Thulin&amp;volume=75&amp;publication_year=1977&amp;pages=181-186&amp;pmid=405214&amp;doi=10.1111/j.1432-1033.1977.tb11515.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R29">
<span class="label">29.</span><cite>Klebe G
Applying thermodynamic profiling in lead finding and optimization. Nat Rev Drug Discov
2015, 14, 95–110.</cite> [<a href="https://doi.org/10.1038/nrd4486" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25614222/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Drug%20Discov&amp;title=Applying%20thermodynamic%20profiling%20in%20lead%20finding%20and%20optimization&amp;author=G%20Klebe&amp;volume=14&amp;publication_year=2015&amp;pages=95-110&amp;pmid=25614222&amp;doi=10.1038/nrd4486&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R30">
<span class="label">30.</span><cite>Ross PD; Subramanian S
Thermodynamics of protein association reactions: forces contributing to stability. Biochemistry
1981, 20, 3096–3102.</cite> [<a href="https://doi.org/10.1021/bi00514a017" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7248271/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochemistry&amp;title=Thermodynamics%20of%20protein%20association%20reactions:%20forces%20contributing%20to%20stability&amp;author=PD%20Ross&amp;author=S%20Subramanian&amp;volume=20&amp;publication_year=1981&amp;pages=3096-3102&amp;pmid=7248271&amp;doi=10.1021/bi00514a017&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R31">
<span class="label">31.</span><cite>Sergeev YV; Dolinska MB; Wingfield PT
Thermodynamic analysis of weak protein interactions using sedimentation equilibrium. Curr Protoc Protein Sci
2014, 77, 20, 13, 1–15.</cite> [<a href="https://doi.org/10.1002/0471140864.ps2013s77" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4182932/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25081741/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Protoc%20Protein%20Sci&amp;title=Thermodynamic%20analysis%20of%20weak%20protein%20interactions%20using%20sedimentation%20equilibrium&amp;author=YV%20Sergeev&amp;author=MB%20Dolinska&amp;author=PT%20Wingfield&amp;volume=77&amp;publication_year=2014&amp;pages=20-15&amp;pmid=25081741&amp;doi=10.1002/0471140864.ps2013s77&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R32">
<span class="label">32.</span><cite>Dolinska MB; Wingfield PT; Sergeev YV
βB1-crystallin: thermodynamic profiles of molecular interactions. PLoS One
2012, 7, e29227.</cite> [<a href="https://doi.org/10.1371/journal.pone.0029227" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3253074/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22238594/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20One&amp;title=%CE%B2B1-crystallin:%20thermodynamic%20profiles%20of%20molecular%20interactions&amp;author=MB%20Dolinska&amp;author=PT%20Wingfield&amp;author=YV%20Sergeev&amp;volume=7&amp;publication_year=2012&amp;pages=e29227&amp;pmid=22238594&amp;doi=10.1371/journal.pone.0029227&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R33">
<span class="label">33.</span><cite>Vicart P; Caron A; Guicheney P; Li Z; Prévost MC; Faure A; Chateau D; Chapon F; Tomé F; Dupret JM; Paulin D; Fardeau M
A missense mutation in the alphaB-crystallin chaperone gene causes a desmin-related myopathy. Nat Genet
1998, 20, 92–95.</cite> [<a href="https://doi.org/10.1038/1765" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9731540/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Genet&amp;title=A%20missense%20mutation%20in%20the%20alphaB-crystallin%20chaperone%20gene%20causes%20a%20desmin-related%20myopathy&amp;author=P%20Vicart&amp;author=A%20Caron&amp;author=P%20Guicheney&amp;author=Z%20Li&amp;author=MC%20Pr%C3%A9vost&amp;volume=20&amp;publication_year=1998&amp;pages=92-95&amp;pmid=9731540&amp;doi=10.1038/1765&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R34">
<span class="label">34.</span><cite>Arrar M; de Oliveira CA; McCammon JA
Inactivating mutation in histone deacetylase 3 stabilizes its active conformation. Protein Sci
2013, 22, 1306–1312.</cite> [<a href="https://doi.org/10.1002/pro.2317" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3795489/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23904210/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Protein%20Sci&amp;title=Inactivating%20mutation%20in%20histone%20deacetylase%203%20stabilizes%20its%20active%20conformation&amp;author=M%20Arrar&amp;author=CA%20de%20Oliveira&amp;author=JA%20McCammon&amp;volume=22&amp;publication_year=2013&amp;pages=1306-1312&amp;pmid=23904210&amp;doi=10.1002/pro.2317&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R35">
<span class="label">35.</span><cite>Bartels T; Choi JG; Selkoe DJ
α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature
2011, 477, 107–110.</cite> [<a href="https://doi.org/10.1038/nature10324" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3166366/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21841800/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=%CE%B1-Synuclein%20occurs%20physiologically%20as%20a%20helically%20folded%20tetramer%20that%20resists%20aggregation&amp;author=T%20Bartels&amp;author=JG%20Choi&amp;author=DJ%20Selkoe&amp;volume=477&amp;publication_year=2011&amp;pages=107-110&amp;pmid=21841800&amp;doi=10.1038/nature10324&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R36">
<span class="label">36.</span><cite>Makley LN; McMenimen KA; DeVree BT; Goldman JW; McGlasson BN; Rajagopal P; Dunyak BM; McQuade TJ; Thompson AD; Sunahara R; Klevit RE; Andley UP; Gestwicki JE
Pharmacological chaperone for α-crystallin partially restores transparency in cataract models. Science
2015, 350, 674–677.</cite> [<a href="https://doi.org/10.1126/science.aac9145" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4725592/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26542570/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Pharmacological%20chaperone%20for%20%CE%B1-crystallin%20partially%20restores%20transparency%20in%20cataract%20models&amp;author=LN%20Makley&amp;author=KA%20McMenimen&amp;author=BT%20DeVree&amp;author=JW%20Goldman&amp;author=BN%20McGlasson&amp;volume=350&amp;publication_year=2015&amp;pages=674-677&amp;pmid=26542570&amp;doi=10.1126/science.aac9145&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R37">
<span class="label">37.</span><cite>Sekijima Y; Dendle MA; Kelly JW
Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid
2006, 13, 236–249.</cite> [<a href="https://doi.org/10.1080/13506120600960882" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17107884/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Orally%20administered%20diflunisal%20stabilizes%20transthyretin%20against%20dissociation%20required%20for%20amyloidogenesis&amp;author=Y%20Sekijima&amp;author=MA%20Dendle&amp;author=JW%20Kelly&amp;volume=13&amp;publication_year=2006&amp;pages=236-249&amp;pmid=17107884&amp;doi=10.1080/13506120600960882&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R38">
<span class="label">38.</span><cite>Schaftenaar G; Noordik JH
Molden: a pre- and post-processing program for molecular and electronic structures. J Comput Aided Mol Des
2000, 14, 123–134.</cite> [<a href="https://doi.org/10.1023/a:1008193805436" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10721501/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Comput%20Aided%20Mol%20Des&amp;title=Molden:%20a%20pre-%20and%20post-processing%20program%20for%20molecular%20and%20electronic%20structures&amp;author=G%20Schaftenaar&amp;author=JH%20Noordik&amp;volume=14&amp;publication_year=2000&amp;pages=123-134&amp;pmid=10721501&amp;doi=10.1023/a:1008193805436&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R39">
<span class="label">39.</span><cite>Pettersen EF; Goddard TD; Huang CC; Couch GS; Greenblatt DM; Meng EC; Ferrin TE
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem
2004, 25, 1605–1612.</cite> [<a href="https://doi.org/10.1002/jcc.20084" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15264254/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Comput%20Chem&amp;title=UCSF%20Chimera--a%20visualization%20system%20for%20exploratory%20research%20and%20analysis&amp;author=EF%20Pettersen&amp;author=TD%20Goddard&amp;author=CC%20Huang&amp;author=GS%20Couch&amp;author=DM%20Greenblatt&amp;volume=25&amp;publication_year=2004&amp;pages=1605-1612&amp;pmid=15264254&amp;doi=10.1002/jcc.20084&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><span>supplemental materials</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/6276790/bin/NIHMS996579-supplement-supplemental_materials.pdf" data-ga-action="click_feat_suppl" class="usa-link">NIHMS996579-supplement-supplemental_materials.pdf</a><sup> (907.8KB, pdf) </sup>
</div></div></section></section></section></section></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1021/acs.jmedchem.8b00817"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/nihms-996579.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.4 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/6276790/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/6276790/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC6276790%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC6276790/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC6276790/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC6276790/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/30133284/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC6276790/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/30133284/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC6276790/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/6276790/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="sY9aB46WaEovm8ncVYhFmPlb43HfZBIxtHWR4Pu870D1GBGx9cmlatNLPRXPCbpb">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
